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ABSTRACT 
This disseration reports the synthesis and biological applications of bifunctional trimeric 
peptides with B7H6-derived NKp30 binding motifs that serve to activate an immunocytotoxic 
response in natural killer cells and a GRP78-binding motif that can target tumors that express 
surface GRP78. In this manner the cancer-targeting immunostimulatory peptides are anticipated 
to directly bind and activate effector NK92-MI cells while also recognizing and binding to target 
A549 tumor cells to facilitate NK cell-dependent immunocytotoxicity of the targeted tumors. The 
NKp30 binding peptide motifs are derived from the tumor associated B7H6 antigen that is often 
downregulated or shed from the surface of tumors resulting in evasion of NK-dependent immunity 
and tumor resistance. Moreover, surface GRP78 is expressed on tumors but not healthy cells 
thereby enabling GRP78-targeting peptides to selectively bind to tumors. Therefore, the 
bifunctional peptides are designed to overcome this limitation and restore NK cell immunity while 
providing targeted cancer immunotherapy in tumors that express surface GRP78. This thesis 
provides a proof-of-concept discovery on the potential to develop bifunctional peptide ligands that 
can restore and/or activate NK cell activity against these tumor types.    
Our preclinical approach initially studied direct and/or competition binding assays of the 
trimeric peptides to both surface NKp30 and GRP78 cell lines, NK92-MI and A549 cells 
respectively, using flow cytometry. From this analysis, a lead synthetic bifunctional trimeric 
peptide 13 displayed binding to the NK and A549 cells with some degree of receptor binding 
specificity. This trimeric peptide also triggered NK-dependent immunostimulatory activity with 
secretion of IFN- and IL-8. In co-culture with the surface GRP78 expressing A549 lung tumor 
cells, the lead trimeric peptide 13 pre-activated NK92-MI cells resulting in observable association 
and cytotoxicity of the target A549 cancer cells, presumably due to the detectable release of 
 vi 
proinflammatory cytokines, TNF-, IFN- and IL-8 from the NK cells. These cell-based assays 
confirmed the capabilities of the lead trimeric peptide 13 to activate NK cell immunity and effect 
immuncytotoxicity of the target A549 tumor cells. The pre-activated NK92-MI cells with the lead 
trimeric peptide 13 also sustained a reduced tumor growth rate when compared to the untreated 
control, thereby also supporting the in vivo immunotherapeutic effects of the lead peptide in mice 
models with the A549 tumor. This pilot study therefore reveals the cancer immunotherapeutic 
potential of a lead cancer-targeting immunostimulatory peptide and paves the way for additional 
investigations that may facilitate its translation from pre-clinical to clinical applications. 
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Chapter 1: Introduction into Natural Killer Cells as an Immunotherapeutic 
Approach 
 
1.1 General Introduction in the Cell Biology of Natural Killer Cells 
1.1.1 The Origin, Differentiation and Proliferation of Natural Killer Cells 
Natural killer (NK) cells are cytotoxic lymphocytes of the innate and adaptive immune 
system that do not require prior antigen exposure, sensitization and activation to mediate 
inflammatory responses.1 These cells originate in the bone marrow and lymphoid tissues such as 
the tonsils, spleen and lymph nodes.1 Based on their origin, NK cells possess differential 
expression of lineage-specific surface markers dividing them into specific subsets. Mature NK 
cells are defined by differential surface expression of CD27 and CD11b (Mac-1).1 During their 
maturation process NK cells do not initially express either receptor, referred to as the double-
negative population.1 They then progress to express CD27+ CD11b- followed by CD27+ and 
CD11b+ referred to as double-positive. The most mature NK cells are CD27- CD11b+ which is 
associated with the acquisition of NK cell effector functions.1 
 The human NK-92 cells are an NK-based immortal cell line that can directly attack and 
eliminate cancer cells.2 The cells were originally derived from peripheral blood mononuclear cells 
of a 50-year-old Caucasian male patient with rapidly progressive non-Hodgkin’s lymphoma as 
first isolated and characterized by the laboratory of Hans Klingermann at the British Columbia 
Cancer Agency in Vancouver, Canada.3 The NK-92 cell line is also classified as IL-2-dependent 
and are positive in antigen expression for the cluster of differentiation (CD) CD2, CD7, CD11a, 
CD28, CD45, CD56 and negative for CD1, CD3, CD4, CD8, CD10, CD14, CD19, CD20, CD23, 
CD34 and human leukocyte antigen isotype DR(HLA-DR) receptors.2,3 The related NK-92MI cell 
 2 
line originated from the NK-92 cell line as a subset that is not dependent on exogenous IL-2 for 
cell growth and proliferation.4 In order to generate the NK-92MI cell line containing endogenous 
IL-2 expression, the NK-92 cells were transfected with human IL-2 cDNA using the retroviral 
MFG-hIL-2 vector by particle-mediated gene transfer and cell line transformation.4,5 All surface 
antigens were found to be the same, with the exception that the NK-92MI cells contained elevated 
levels of CD54+ and reduced levels for CD16-.5 
 
 
Figure 1.1. Origin, proliferation and differentiation of natural killer cell lymphocytes. 
© 2018 Abel, Yang, Thakar and Malarkannan. 
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1.1.2 The Activating and Inhibitory Natural Killer Cell Receptors and their Regulatory 
Ligands 
The cell surface of an NK cell is present with activating and inhibitory cell receptors.6 
Among the activating receptors are the NKG2D, the signaling lymphocytic activation molecule 
(SLAM) family molecule 2B4 (CD244), the DNAX accessory molecule (DNAM-1, CD266) and 
the natural cytotoxic receptors (NCRs).6 Rather than a dominant activating receptor, NK cell 
receptors function in a synergistic manner to activate NK cells’ effector functions.6 
NKG2D is a homo-dimeric receptor of the C-type lectin superfamily that serves as a major 
recognition receptor for detection and elimination of infected cells.6 This receptor is expressed on 
all NK cells and a subset of T cells.6 Ligand binding and modulation of  the human NKG2D 
receptor is contingent upon cellular stress such as DNA damage, heat shock or cellular 
transformation.6 These ligands include the MHC I-related molecules (MICA and MICB) and the 
UL16-binding proteins (ULBP-1 to ULBP-6).6 They are rarely expressed in healthy tissues while 
frequently expressed on primary tumors such as urothelial tumor and bladder cancer cell lines, or 
on antigen presenting cells (APCs) including macrophages and dendritic cells.6 However, tumors 
may develop mechanisms to evade or evolve resistance towards NK cells’ effector functions.6 The 
mechanisms include downregulation or inhibition of the activating NKG2D receptor in NK cells 
and is often associated with cancer recurrence and resistance.6  
The member of the SLAM receptor family, 2B4, has been extensively characterized as an 
NK cell activation receptor.6 Binding of 2B4 with 2B4-specific antibodies or the natural ligand 
CD48, induces IFN production and NK cell-mediated cytotoxicity.6 The DNAX accessory 
protein, DNAM-1, has been characterized as an Ig-type family glycoprotein expressed on most 
human NK cells as well as monocytes and T lymphocytes.6 Ligands for DNAM-1 include two of 
 4 
the nectin family proteins (CD112 and CD155) that are regulated by cellular stress. These ligands 
are expressed in a wide range of tumors and expression of CD155 and CD112 in patients correlates 
with tumor cell invasion by NK cell cytotoxicity.6 
The NCRs are a family of transmembrane proteins within the immunoglobulin superfamily 
that can be stimulated to release inflammatory cytokines such as IFN and TNF resulting in NK 
cell killing activity.7 Human NK cells express three types of NCRs on their cell surface including 
NKp46 (NCR1; CD335), NKp44 (NCR2; CD336) and NKp30 (NCR3; CD337) and bind to 
activating and inhibitory circulating ligands that regulate NK cell activity (Figure 1.2).7,8 The 
NCRs were discovered in the late 1990s when they were originally grouped together for their 
ability to activate NK cells since their sequence and structure were unknown.8 They were 
distinguished as important for the killing of tumor cells in vitro.8 Since then, the NCRs have been 
characterized based on  amino acid primary sequence as well as higher-level structure composition 
(Figure 1.2).8 Together, they are classified as type I transmembrane proteins composed of one or 
two extracellular immunoglobulin-like domains responsible for ligand binding.8 The 
transmembrane domain interacts with signaling adaptor proteins that contain immunoreceptor 
tyrosine-based activation motifs (ITAMs) within the domain.8 
 5 
 
Figure 1.2. Structural domains and ligand binding sites of the NCRs; NKp30, NKp44, NKp46.  
© 2013 Koch, Steinle, Watzl and Mandelboim. 
 
The NKp46 receptor was classified as the first and only NCR conserved in both humans 
and mice.8 The NKp46 receptor is expressed on active and resting NK cells as well as in a discrete 
subsets of T cells ( and ) and a subset of group 3 innate lymphoid cells (ILCs) (NCR+ ILC3).8 
Patients with coeliac disease possess NKp46-expressing intraepithelial T lymphocytes.8 The 
NKP46 gene is located on the human chromosome 19 (19q13.42).8 The structure is composed of 
a long stalk domain of 40 amino acids, a single transmembrane domain and a highly charged 
cytoplasmic region of 25 amino acids.8 There are two N-terminal C2-type Ig domains arranged at 
an 85 angle and connected by a hinge region that is likely involved in ligand binding.8 The 
 6 
cytoplasmic tail contains CD3 and FcR adaptor proteins that activate NK cells through their 
ITAM motifs which bind NKp46 at an arginine in the transmembrane domain.8 The proteins of the 
killer cell immunoglobulin family, ILT2 (CD85j, LLRB1), glycoprotein VI and FcRI show 
structural similarities to NKp46.8 
The NKp44 receptor is expressed on activated NK cells and may be found on other cells 
including decidual NK cells and a subset of plasmacytoid dendritic cells in the tonsils.8 The protein 
is encoded by the NKP44 gene in the class III region of the human MHC locus on chromosome 6 
(6p.21.1).8 The structure is composed of a long stalk domain of 64 amino acids, a single 
transmembrane protein and a short cytoplasmic tail of the following sequence (EILYHTVA) that 
represents the ITAM motif.8 There is a single extracellular V-type Ig domain which contains a 
ligand binding site found in the highly positive-charged groove within the Ig-V domain.8 The 
cytoplasmic tail containing an ITAM interacts with a positive lysine in the transmembrane region 
to activate the NK cell immunity.8  
The NKp30 receptor is expressed on all mature NK cells and may be expressed on cord 
blood T cells after IL-15 exposure, on V1+ T cells upon TCR engagement while in the presence 
of IL-2 and IL-15 with endometrial epithelial cells after progesterone stimulation.8 The NKp30 
receptor is encoded by the NKP30 gene in the class III region of the human MHC locus on 
chromosome 6 (6p.21.1).8 The structure is composed of one extracellular immunoglobulin domain, 
a transmembrane domain and an intracellular domain.9 The transmembrane domain contains a 
charged arginine while the intracellular domain has no signaling domains.9 The NKp30 receptor 
mediates NK cell activation when CD3 homodimer or CD3/FcR heterodimer bind the charged 
arginine in the transmembrane domain.9 The NKp30 protein may differ from six different splice 
variants. Three of these splice variants (NKp30a, NKp30b and NKp30c) possess an extracellular 
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V-type domain whereas the others (NKp30d, NKp30e and NKp30f) contain a C-type Ig domain.9 
Differences in exon 4 translation accounts for splicing alternations in the intracellular domains.9 
This combination of NKp30 spliced isoforms leads to differences in NK cell responses.9 For 
instance, high quantities of IFN were released when NK cells were transfected with vectors 
expressing NKp30a and NKp30b, whereas IL-10 and only a small amount of IFN were produced 
upon NK cell transfection with vectors expressing NKp30c.9 This concluded that the NKp30a and 
NKp30b spliced variants are immunostimulatory isoforms of NKp30  able to release TH1 cytokines 
while NKp30c is the immunosuppressive isoform as observed by IL-10 production.9 Within the 
receptor structure, a reduced association with CD3 was detected following crosslinking with the 
NKp30c isoform, which did not occur in NKp30a and NKp30b isoforms.9 In the clinic, this 
phenomenon is observed as gastrointestinal stromal tumor.9 Patients that express NKp30c isoform 
have a worse prognosis and outcome compared to patients that express NKp30a or NKp30b 
isoforms.9 
The discovery of cellular ligands for the NCRs has also been established on normal and 
transformed cells (Table 1.1).10 Heparan sulphate (HS) is an activating NCR ligand present on all 
animal cells but with varying expression patters on healthy tissues and tumor cells.10 The NKp30 
and NKp46 receptors detect and bind to membrane-associated HS proteoglycans.10 The ligand: 
receptor binding interaction is influenced by HP expression levels on the cell surface.10 While the 
binding pattern of HS on NKp30 or NKp46 is similar, the binding affinity varies markedly.10 
Overall, the NCRs bind to structures containing two to three sulphate groups per disaccharide unit 
such that the units are sulphated above average.10 It is proposed that HS functions as a cofactor in 
complex with other ligands to modify the NK cell response.10 HS interferes with interactions 
between NCR and HP glycosaminoglycans on the NK cell surface.11 
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The proliferating cell nuclear antigen (PCNA) was the first ligand identified for the NKp44 
receptor.8 It was observed that overexpression of recombinant PCNA in IL-2 activated primary 
NK cells reduced IFN secretion thereby functioning as an inhibitory ligand.8 PCNA is 
overexpressed in tumor cells but may also be overexpressed in normal cells such as decidual 
trophoblasts in the first trimester of gestation.8 The NKp44L is an NKp44 receptor ligand with  
partial similar sequence to the mixed-lineage leukemia protein 5 (MLL5) gene, an important 
regulator of the cell cycle.8 The difference occurs in the NKp44L C-terminal exon which lacks the 
last 5 exons of MLL5.8 Moreover, MLL5 is almost exclusively expressed in the nucleus whereas 
NKp44L expression is localized in the cytoplasm.8 Both expression of MLL5 and NKp44L varies 
in different tissues.10,11 Healthy tissues such as the lungs and testes express a marginal amount of 
NKp44L.8 However, NKp44L is not expressed in any otherwise healthy tissues.8 The NKp44L is 
classified as an activating ligand that induces NK cytotoxicity by binding to NKp44 on the NK 
cell surface.12  
The HLA-B-associated transcript 3 (BAT3) is an activating NKp30 ligand that is also 
referred to as BCL2-associated anthogene 6.13 BAT3 is involved in p53-mediated cellular response 
to stress and DNA damage and apoptosis.13 Expression of BAT3 is localized to the nucleus in 
healthy cells, but is upregulated in the cytoplasm of tumor and apoptotic cells.13  Although BAT3 
binds to NKp30, it is not considered a tumor cell surface ligand because of its characterization as 
a nuclear protein released upon heat shock treatment.13 Instead, BAT3 is proposed as an activating 
ligand for NKp30 on dendritic cells only.13 
The B7H6 is an NKp30 activating ligand and a member of the B7 family.13 The structure 
consists of two extracellular Ig domains. B7H6 interacts with NKp30 by the front -sheet of the 
V-like domain of B7H6 and the front and back -sheets of the C-like domain of NKp30.13 In 
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particular, N-linked glycosylations of NKp30 are important for ligand binding and intracellular 
signaling.13 B7H6 expression is present on the surface of many tumor cell lines and CD16+CD14+ 
proinflammatory monocytes and neutrophils when activated by Toll-like receptors or 
proinflammatory cytokines (IL-1 and TNF).13 In the clinic, increased mortality in a group of 
patients with sepsis was observed and linked to B7H6 expression on monocytes.13 NK cells can 
utilize B7H6 to detect different tumor cells and proinflammatory monocytes or neutrophils in 
inflammatory conditions or ones related to NK-dependent immunosurveillance.13  
NK cells have two major classes of inhibitory receptors including KIR and CD94-NKG2A 
heterodimer.14 KIR is a type I transmembrane receptor with extracellular Ig-like domains and 
recognizes HLA-C expression on target cells.14 NKG2A is a type II transmembrane receptor that 
belongs to the CD92-NKG2 C-type lectin family and recognizes non-classical HLA-E expression 
on target cells. Both KIR and NKG2A signal through immunoreceptor Tyr-based inhibitory motif 
(ITIM) with the consensus amino acid sequence of V/IxYxxL/V.14 While ITIM recruits Tyr 
phosphatase SHP-1 or SHP-2, ITIM-dependent inhibition of NK cell activation prefers recruitment 
of SHP-1 to the ITIMs.14 SHP-1 is composed of two tandem SH2 domains, a catalytic domain and 
a C-terminal tail.14 Regulation of SHP-1 occurs in the cytosol as it exists in an auto-inhibited 
conformation.14 This auto-inhibition is relieved as SHP’s tandem SH2 domains bind with ITIMs 
to activate catalytic activity of SHP-1.14 Interestingly, these inhibition signals can interrupt 
activation of NK cells by a variety of mechanism such as adhesion to target cells, clustering of 
activating receptors, and Ca2+ flux.14 The NK cell inhibitory receptors can accumulate rapidly at 
inhibitory synapses that then blocks proximal activation signals such as actin-dependent adhesion 
and clustering of activating receptors.14 Blocking proximal activation signals allows NK cell 
inhibitory receptors to dominate over activating receptors.14  
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Receptor Ligand Ligand localization Effect on NK cell 
activation 
NKp30 B7-H6 Plasma membrane + 
BAG6 Nucleus, plasma membrane, 
exosomes 
+ 
Pp65 Cytosol - 
pfEMP1 Plasma membrane + 
Viral HA Plasma membrane - 
Heparin or heparan 
sulfate 
Plasma membrane + 
NKp44 Sialylated and 
sulfated 
proteoglycans 
Plasma membrane + 
Viral HA and HN Plasma membrane + 
PCNA Cytosol - 
Heparin or Heparan 
sulfate 
Plasma membrane + 
NKp46 Viral HA and HN Plasma membrane + 
Heparin or heparan 
sulfate 
Plasma membrane + 
Table 1.1. List of activating and inhibitory NK cell receptors and their ligands.7 
©2013 Koch, Steinle, Watzl and Mandelboim with permission. 
 
1.1.3. Resistance and Evasion Mechanisms   
Not all tumor cell lines have cell surface B7H6 expression and therefore cannot be 
recognized by NK cells.15 This is a hallmark mechanism of tumor immunoevasion, or evasion of 
the immune system.15 In this resistance mechanism, tumor cells utilize catalytic metalloproteases 
including “a disintegrin and metalloproteases” ADAM-10 and ADAM-17.16 These  
metalloproteases are commonly referred to as sheddase for their ability to cleave membrane 
proteins at the cell surface and thereby alter their location and function.16 ADAM10 is a sheddase 
whose catalytic mechanism is based on peptide hydrolysis (Scheme 1.1).16 This protease contains 
an active site that is homologous to zinc-proteases and it is therefore proposed that the key catalytic 
elements include a His-stabilized Zn2+ ion and a glutamate residue at the enzyme active site.16 This 
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mechanism begins with the deprotonation of a water molecule by glutamate to generate the 
nucleophilic hydroxide anion.16 The hydroxide anion then initiates a nucleophilic attack on a 
carbonyl carbon on the peptide backbone to produce a tetrahedral alkoxide ion intermediate.16 The 
Zn2+ ion functions as a Lewis acid, stabilizing the alkoxide anion intermediate.16 The tetrahedral 
alkoxide intermediate then collapses and eliminates the linking amide bond via protonation of the 
-NH by the glutamate residue.16 The carboxylate group is also released from the enzyme active 
site and the water molecule is regenerated at the of the catalytic mechanism. 
 
 
Scheme 1.1. Reaction mechanism associated with ADAM10-catalyzed shedding of surface 
proteins.14 
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In the clinic, selective ADAM10 inhibitors are administered in combination with low doses 
of Herceptin (Trastuzumab), a monoclonal antibody specific for the HER2+ receptor in breast 
cancer.16 This combination therapy decreases proliferation of HER2 over-expressing breast cancer 
cell lines. Here, ADAM10 assists in HER2 shedding, while combination of inhibitor and antibody 
treatment respectively restricts HER2 shedding and signaling activity.16 The ADAM-17 
metalloprotease is also referred to as tumor necrosis factor alpha converting enzyme (TACE) as it 
is involved in the processing of TNF at the cell surface.16 Similar to ADAM10, ADAM17 is 
classified as a sheddase, but is instead involved in the cleavage of membrane-bound pro-proteins 
(such as pro-TNF).16 For example, ADAM17 is responsible for the proteolysis of pro-TNF that 
is cleaved at the Ala76-Val77 amide bond and releases an ectodomain from the pro-TNF 
molecule to generate the active TNF cytokine.16  
Normal cells present an adequate density of ligands for inhibitory signals to inhibit NK 
cells from being activated.8 In stressed cells, the expression of inhibitory signals is dramatically 
reduced thereby leading to NK cell activation, known as “missing self” recognition.8 In human 
NK cells, the immunoglobulin-like inhibitory receptors interact with HLA-A, HLA-B, HLA-C and 
the C-type lectin-like inhibitory receptors (such as CD94-NKG2A) interact with non-classical 
HLA-E.8 The NKG2D homodimers interact with MHC class I chain-related proteins A and B 
(MICA and MICB) that are stress-induced molecules and UL16-binding proteins (ULBPs).8 
Among the additional inhibitory receptors are the killer-cell immunoglobulin-like receptors 
(KIRs), the CD94 heterodimer, the immunoglobulin-like receptor (ILT) and the Ly49 
homodimer.17  The KIRs are the main receptors for classical MHC I (including HLA-A, HLA-B 
and HLA-C) and function by inhibition of NK cell killing.17 The CD94 heterodimer is a C-type 
lectin family receptor coding for nonclassical MHC I molecules such as HLA-E.17 The ILTs are 
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IgG-type receptors.17 Overall, NK cells preferentially kill target cells that possess low levels of 
MHC class I on their cell surface, a phenomenon known as the “missing-self recognition”. Since 
the MHC class I receptors are the main mechanism by which cells display antigens to cytotoxic T 
cells they have minimal effects on NK cell immunity.17  
 
1.1.4. NK Cell Proliferation and Trafficking 
The primary location of NK cell development is the bone marrow. The lymph nodes and 
thymus have also been proposed as alternative locations.18 During this developmental stage, NK 
cells go through a complex maturation process leading to pronunciation of their effector 
functions.18 They may gain, or lose expression of cell surface markers CD11b and CD27.18 The 
predominate NK cells located in the bone marrow and lymph nodes are CD11b- NK cells whereas 
in the blood, liver, spleen and lung are CD27- NK cells. The location of final maturation for NK 
cells remains unknown.18 
However, it is known that NK cell maturation is correlated with acquisition of one of the 
five sphingosine-phosphatase (S1P) G-protein-coupled receptors, S1P5.18 The S1P receptor is 
secreted as a lysophospholipid bound to albumin. It is biosynthetically maintained by sphingosine 
kinases or degraded by sphingosine lyase and phosphatases.18 The extracellular fluids contain high 
S1P concentrations whereas the tissues contain low S1P concentrations.18 In NK cells, S1P5 
functions as a chemotactic receptor for S1P to promote NK cell homing in the blood, spleen and 
lung.18 Likewise, S1P5 expression directly correlates with NK cell accumulation in the bone 
marrow and lymph nodes.18 NK cells enter the lymph nodes through high endothelial venules 
(HEVs).18 The NK cells express L-selectin (CD62L) that allows the interaction with glycosylated 
L-selectin ligands found on the HEVs.18 NK cells then enter into the spleen through the marginal 
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sinus where they are localized in the red pulp surrounding the white pulp.18 NK cells localization 
to the spleen is believed to be reached by default in the absence of CCR7 expression.18 
NK cells bound for non-lymphoid organs are thought to travel there in a S1P5-independent 
manner by being carried in the blood flow.18 Inflammation requires a series of sequential molecular 
interactions between leukocytes and endothelial cells.18 This recruits NK cells to the site of 
inflammation by the expression of chemokines.18 Certain inflammatory receptors are then 
expressed including CCR2, CCR5, CXCR3 and CX3CR1 that allow NK cells to respond to the 
inflammatory cytokines (including CCL2, CCL3, CCL5, CCL7, CCL8, CCL9, CCL11, CCL13, 
CDCL9-11 and CX3CL1).18 A limited set of chemokines can produce a broad response.18 Once 
activated by chemokines, NK cells then interact with the endothelium via integrins.18 Here, NK 
cells will express different integrins over the course of development and maturation.18 Mature NK 
cells may be indicated by decreased expression of CD11c and CD61 (beta3 integrin).18 During 
liver inflammation, NK cells are recruited by chemokines such as CCR1 and CXCR3.18 CCR1 
aids in mobilization of NK spleen cells while CCR1 aids in NK cell accumulation in the liver.18 
Van Helden et al. showed that NK cells proliferate mostly in the bone marrow and not at the site 
of infection upon influenza infection.19 They also demonstrated that there is an increase in NK 
cells in the airways as a result of migration.19  
 
1.1.5. NK-Dependent Toxicity 
NK cells are cytotoxic immune cells containing small granules in their cytoplasm that 
contain cytolytic (membrane disrupting) enzymes such as perforin and granzymes.2,3 Perforin is a 
pore-forming cytolytic protein that binds to the plasma membrane cells to utilize Ca2+ and 
oligomerize to form pores on the target cell.2,3 Once pores are generated, passive diffusion of 
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granzymes, pro-apoptotic proteases, occurs.2,3 More specifically, granzymes are serine proteases 
that induce apoptosis, programmed cell death, by activating caspases such as caspase-3 that cleaves 
many cellular substrates. This includes Bid, or the BH3 interacting-domain death agonist and a 
proapoptotic member of the Bcl-2 family, that leads to the release of cytochrome c from the 
mitochondrial membrane.2,3  
Further, activation of NK cells results in recruitment of subsequent cytolytic effector cells 
such as macrophages, dendritic cells and neutrophils that ultimately lead to antigen-specific T and 
B cell responses. 4,5 Upon recognition and binding to cancer cells, NK cells also secrete cytolytic 
enzymes such as perforin and granzymes to induce apoptosis in target cells.4,5 They may also 
utilize the Fas-Fas ligand system.4,5 Fas forms the death-inducing signaling complex (DISC) upon 
ligand binding leading to trimerization of Fas receptor and ultimately leading to the activation of 
caspase-8 that results in DNA degradation and membrane disruption.4,5  
NK cell cytotoxicity is mediated by the NCRs and the low-affinity IgG receptor CD16 that 
allows the cells to recognize and kill target cells by opsonization in an antibody-dependent 
manner.20 NK cells also possess secretory lysosomes with cytotoxic proteins such as granzymes 
and perforin.20 The secretory lysosome is released from the NK cell upon recognition of the target 
cell and the cytotoxic contents are released.20 Here, the entry of granzymes into the target cell is 
facilitated by perforin.20 Granzymes then cleave caspases that result in cell death.20 
 
1.2 Natural Killer Cell Immunology  
1.2.1. Mechanism Associated with NK Cell-Dependent Immunostimulatory Activity  
Normal, healthy cells express MHC class I molecules on their surface that function as 
ligands for inhibitory receptors.21 Virus-infected or tumor cells lose surface MHC class I 
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expression that thereby lowers inhibitory signals.21 Ligands for activating receptors are 
upregulated under cell stress such as DNA damage, senescence or increase in expression of tumor 
suppressor genes.21 NK cell activation is followed by secretion of cytokines including IFN, 
TNF, granulocyte macrophage colony-stimulating factor (GM-CSF) and chemokines (CCL1, 
CCL2, CCL3, CCL4, CCL5 and CXCL8).21  
 The complexes between activating receptors and their ligands lead to phosphorylation of 
ITAM by Src family of tyrosine kinases (Lck, Fyn, Src, Yes, Fgr and Lyn).21 Phosphorylation of 
ITAM subunit results in recruitment and activation of the tyrosine kinase Syk and Zap70.21 Zap70 
phosphorylation then induces a downstream signaling pathway including phosphorylation of SLP-
76, Shc and phosphatidylinositol-3-OH kinase followed by assembly of Grb2 and activation of 
mitogen-activated protein kinases (MAPKs) and extracellular signal-regulated kinases (ERKs).21 
The final outcome is elevation of calcium levels, transcription of genes for cytokines and 
chemokines, and the release of cytolytic granules containing perforin and granzymes.21 
NK cells are also activated by antibody recognition of CD16 receptors on the NK cell 
surface to release cytolytic granules that allow for cellular apoptosis.2,3 Cancer treatments have 
utilized this strategy in the formation of monoclonal antibodies such as rituximab (Rituxan) and 
Ratumumab (Azzera).2,3 These studies have utilized a type of NK cell commonly referred to as 
NK-92 to measure antibody-dependent cell-mediated cytotoxicity (ADCC) in tumor cells 
transfected with high affinity CD16 receptors.2,3 
Cytokine-induced activation of NK cells is among the most common methods for NK cell 
expansion and activation. In this application, B7H6 binding to NKp30 induces cytokines that are 
present as stress molecules to be released from the NK92-MI cells upon infection and serve to 
signal the presence of pathogens in the affected area.2,3 The NK cells are also activated upon 
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response to interferons or macrophage-derived cytokines.2,3 Cytokines involved in NK cell 
activation include IL-12, IL-15, IL-18, IL-2 and CCL5.2,3 Cytokine activation is mediated by a 
synergistic combination of receptors, allowing a convergence of signals toward a central signaling 
molecule to reach the threshold required for activation of NK cells. NK cells will also secrete pro-
inflammatory cytokines such as IFN and TNF in response to infection or tumor detection (Figure 
1.3).2,3 IFN activates macrophages for phagocytosis and lysis whereas TNF promotes direct 
killing by NK cells.2,3 
 
Figure 1.3. Cytokine-dependent immunostimulatory activity of NK cells.  
© 2017 Paul and Lal. 
 
1.3 Natural Killer-Dependent Cancer Immunotherapy 
1.3.1. Natural Killer-Dependent Cancer Immunosurveillance and Immunotherapy 
NK cells play a significant role in tumor immunosurveillance and immunotherapy since they are 
cytolytic effector lymphocytes directly inducing tumor cell death.4,5 T cells are unable to recognize 
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pathogens in the absence of surface antigens thereby making the role of NK cells critical.4,5 Upon 
tumor cell detection, NK cells are activated to produce and release cytokines including TNF, 
IFN and IL-10 which promotes proinflammatory responses.4,5 This is exceptionally important 
since tumor cells that do not cause inflammation are regarded as self and will not induce a T cell 
response. 4,5 A variety of NK-dependent pre-clinical and clinical studies have been developed for 
treating a wide range of human cancers.  
 
1.3.2. Translation of Preclinical to Clinical Applications of Natural Killer Cells in Cancer 
Immunotherapy 
1.3.2.1 Peripheral Blood-Derived Autologous or Allogeneic Natural Killer Cells for Tumor 
Immunotherapy 
NK cell infusions have been well tolerated without graft-versus-host-disease (GVHD), 
cytokine release syndrome (CRS) or neurotoxicity in several clinical trials.22 One trial showed that 
patients receiving infusions of haploidentical NK cells with high-risk MDS and AML had 
objective responses.22 In another phase I trial, patients with gastric or colorectal cancers underwent 
adoptive NK cell therapy in combination with trastuzumab or cetuximax chemotherapy.22 In this 
trial, tumor sizes in three of the four stable patients were reduced with an increase in IFN 
production and a decrease in the number of T cells.22 
 
1.3.2.2. Natural Killer Cells Derived from PB, UCB and Induced Pluripotent Stem Cells for 
Tumor Immunotherapy 
NK cells derived from the peripheral blood (PB), umbilical cord blood (UCB) and induced 
pluripotent stem cells (iPSCs) are all sources of effector NK cells.22 The large-scale clinical-grade 
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expansion for UCB- and IPSC-derived NK cells has been well established and the antitumor 
activity of these NK cells has been evaluated in hematological and solid cancers.22 However, UCB- 
and iPSC-derived NK cells have poorer or similar antitumor functions when compared with PB 
mononuclear cell (PBMC)-derived NK cells and decreased expression of KIRs that raises concern 
about NK cell effector capacities.22 There are currently five clinical studies focused on UCB-
derived NK cells for hematological and solid tumors.22 The results demonstrated two of the fifteen 
patients treated with UCB-derived NK cells possessing hematological cancers were disease-free 
with an extended lifespan of 6 months following treatment.22 
 
1.3.2.3 Natural Killer Cell Line-Based Tumor Immunotherapy 
The NK-92 cell line is a well-established cell line that offers several advantages in clinical 
practice.22 This cell line is cost effective for patients since it is readily expandable.22 Further, the 
cell line may be easily manipulated using viral or non-viral vectors to enhance characteristics such 
as targeting and killing activity.22 A phase I clinical trial demonstrated the safety and feasibility of 
IL-2-activated NK-92 cells in three out of seven patients with refractory and relapsed AML.22 
 
1.3.2.4 Potential Immunotherapeutic Benefits of Memory-Like Natural Killer Cells 
Memory-like NK cells have higher expression levels of NKG2C, proliferate and maintain 
persistent long-term immunity following prior sensitization. They also possess  increased IFN  
secretion after stimulation with antigens or cytokines.22 These cells are derived by pre-activation 
of human PB-derived NK cells with various combinations of cytokines including IL-12, IL-15 and 
IL-18.22 Preclinical studies found preactivated NK cells displaying antitumor activity against AML 
in a xenograft mice model.22 These cells were then adopted to a clinical study in which transferred 
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memory-like NK cells proliferated and reached a peak from day 7 to day 14 making them useful 
for long-term immunity.22 
1.3.2.5 CAR-NK Cells for Tumor Immunotherapy 
Chimeric antigen receptor (CAR) T cells are prepared from patients’ T cells derived from 
autologous blood to prevent GVHD.22 While effective, this strategy is personalized, time-
consuming and costly.22 Here, NK cells from the blood are gathered and a chimeric antigen 
receptor is expressed within the transformed cell lines (Figure 1.4).22 The new CAR-NK cells may 
now recognize target cells such as cancer cells that are otherwise invisible.22 CAR-NK cells are 
prepared as “off-the-shelf” and not restricted by autologous cells and therefore safe with unlikely 
GVHD outcomes.22 In addition, CAR-NK cells secrete restricted levels of IFN  and GM-CSF but 
do not secrete cytokines responsible for CRS such as IL-1 and IL-6.22 Preclinical studies on CAR-
NK cells have shown antitumor efficacy in murine tumor-bearing mice models.22 In this 
application, the transfer of wild-type epidermal growth factor receptor and EGFRvIII-targeting 
CAR-NK-92 cells significantly reduces the growth of glioblastoma and prolongs survival in 
tumor-bearing mice.22 However, some factors must be overcome before transition to the clinic 
including the short persistence of CAR-NK cells and low transfection efficiency of the PB-derived 
NK cells.22 
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Figure 1.4. Natural killer cell cancer immunotherapeutic strategies.  
© 2019 Hu, Tian and Zhang. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher 
Education Press Limited Company. 
 
1.4.Selection of B7H6-Derived Peptides for Natural Killer Cell Immunity 
The project described in this thesis is based on the thesis work of Mariana Phillips, Ph.D. 
while working in the labs of Drs. Bitsaktsis and Sabatino at Seton Hall University.23 This work has 
also been published and sets an important precedence for the project described in my dissertation.24 
The investigation was based on the discovery of de novo B7H6-derived cytotoxic 
immunostimulatory peptides.24 The design mechanism was based on the crystal structure analysis 
of the binding interface of the immunostimulatory ligand, B7H6 and the NKp30 activating receptor 
found on the surface of NK cells.24 Primary sequence mapping of the B7H6-NKp30 ligand-
receptor binding interactions revealed a series of chemical bonding interactions based on two 
hydrogen bonds between B7H6 (Thr127 and Pro128) with NKp30 (Gly51 and Val53), sixteen Van 
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der Waals interactions between residues 125-130 of the FG loop region of B7H6 (VTPLK) with 
NKp30 residues and one salt bridge interaction between B7H6 at Lys130 with NKp30 at Glu111.24 
Additional Van der Waals interactions were found to occur at residues 59-62 within the BC loop 
region and 82-82 within the C’C” region of the B7H6.24 Using this chemical information, peptides 
were designed to mimic the B7H6-NKp30 interaction.24 
A series of short peptide sequences were selected from the B7H6 binding domains to 
enhance NKp30 binding and activation of NK cells.23-25 A small peptide library was generated, 
based upon one peptide (FGTSMGVTPLK) selected on its similarity to the primary binding 
sequence of B7H6.25 Another peptide sequence (TSMGFGVTPLK) was selected from the binding 
residues of B7H6 that generated a turn-type secondary structure based on the VTPLK sequence 
bound to the NKp30 receptor active site.23-25 The observed binding interaction was hypothesized 
to be due to the turn-type geometry that stabilized the Pro-Leu residues at the i+ 2 and i + 3 
positions.23-25 From this primary sequence, a de novo peptide, TVPLN, was designed to study the 
effect of hydrogen bonding and turn conformation on peptide binding activity.23-25 In this 
sequence, the N-terminal Thr was substituted for Val while the C-terminal Lys was replaced with  
Asn.23-25 The selected peptide (TVPLN) was derived from the VTPLK sequence found in the FG 
loop region of this binding site and was hypothesized to improve NKp30 binding by stabilizing 
the bio-active turn conformation found at this site (Figure 1.5).23-25 Together, these modifications 
promoted turn conformations with the terminal Thr and Asn residues promoting stabilizing 
hydrogen-bonding interactions as detected by CD spectroscopy.23-25 Random amino acid 
substitutions were also used to generate control peptides. In order to track cell biology, fluorescein 
isothiocynate (FITC) was incorporated into the sequence by an aminohexanoic aid (Ahx) linker at 
the N-terminus.25 
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Figure 1.5. Rational design and binding interface of the selected TVPLN sequence for the NKp30 
receptor. 24  
©2016 Phillips, Romeo, Bitsaktsis, and Sabatino with permission. 
 
The peptide sequences were constructed by Fmoc-based solid phase peptide synthesis 
(Fmoc SPPS) on a Rink amide linker hydrophilic poly(ethylene glycol) (PEG) resin.25 Reverse 
phase high performance liquid chromatography (RP HPLC) was used to determine peptide crude 
yields (19-88%) and purities (13-95%).25 Semi preparative RP HPLC was used to further purify 
peptides which were isolated in purities >93% and yields (10-44%).25 Mass spectrometry was used 
to confirm identities of synthetic peptides by validation of the sequence composition based on 
mass/charge ratio (Table 1.1).25 
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Table 1.2. List of peptides synthesized in this study and their characterization data.24  
©2016 Phillips, Romeo, Bitsaktsis, and Sabatino with permission. 
 
 
Peptide biology was next evaluated by initially analyzing the capabilities of the synthetic 
peptides to bind directly to the human NK cell line NK92-MI.23,24 Here, FITC-labeled synthetic 
peptides were incubated with NK92-MI cells for 30 minutes at various concentrations (0.1, 1 and 
10 M) in PBS. Soluble B7H6-Fc (1 M) and the anti-NKp30 APC-labeled mAb (2 g ml-1) were 
used as comparable controls for evaluating peptide binding efficiency.23,24 Binding occupancy was 
measured at 10 µM (80-97%), 1 µM (24-50%)  and 0.1 µM (3-4%) in a dose-response (0.1-10 
M) manner (Figure 1.6).23,24 At a concentration of 10 M, the FITC-labeled synthetic peptides 
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occupied NK cells comparable to the B7H6 ligand and anti-NKp30 mAb according to flow 
cytometry.23,24  
Validation of the NKp30 binding specificity of the selected peptides was confirmed by a 
newly developed competitive displacement assay. The NK92-MI cells were initially treated with 
the FITC-labeled trimeric peptide (10 M in 1X PBS) for 15 min (RT, dark). After which, NK 
cells were washed with FACS buffer, centrifuged and treated with the APC-labeled human NKp30 
mAb (5 L in 1X PBS) for another 15 minutes (R.T., dark). Cells were then washed with FACS 
buffer and analyzed by flow cytometry to reveal some degree of peptide displacement from the 
NK cells upon mAb treatment (Figure 1.7). The synthetic peptides (6-35%) and B7H6 (69%) were 
both partially displaced from the NK92-MI cells by the anti-NKp30 monoclonal antibody.23,24 
These binding experiments proved the selected B7H6 derived peptides bound to NK cells with 
some NKp30 dependence. 
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Figure 1.6. B7H6-derived peptides were confirmed for their ability to directly bind NK92-MI cells 
through a series of direct binding assays.24 
©2016 Phillips, Romeo, Bitsaktsis, and Sabatino with permission. 
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Figure 1.7. B7H6-derived peptides were confirmed for their specificity to recognize NKp30 on 
NK92-MI cells through a series of competitive displacement assay.24 
©2016 Phillips, Romeo, Bitsaktsis, and Sabatino with permission. 
 
 
An enzyme-linked immunosorbent assay (ELISA) was employed to determine the 
immunostimulatory activities (if any) of the synthetic peptides onto the NK cells. The secretion of 
the inflammatory cytokines, TNF and IFN, was studied by ELISA which revealed secretion of 
TNF with B7H6 (>500 pg/ml), and the synthetic peptides (<100-180 pg/ml) treatment (Figure 
1.8). Under these experimental conditions, no significant quantities of IFN was detected. Among 
the peptide series, the TVPLN sequence produced the most significant cytokine release (180 
pg/ml) from the NK cells in a NKp30-dependent manner. 
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Figure 1.8. Cytokine secretion from NK92-MI cells following treatment with B7H6-derived as 
determined by ELISA.24 
©2016 Phillips, Romeo, Bitsaktsis, and Sabatino with permission. 
 
Taken together, a lead peptide sequence, TVPLN, was selected as maintaining good NK cell 
binding activity in an NKp30 dependent manner while maintaining the capabilities of activating 
NK cell secretion of the inflammatory cytokine, TNFα. This peptide behaves as a NK cell targeting 
immunostimulatory peptide that can be applied to cancer immunotherapy applications. To our 
knowledge, the design and application of this peptide is novel and may restore recognition of 
otherwise invisible cancer cells by restoring NK cell recognition and immunity of resilient B7H6- 
cancer cells. 
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1.5 Thesis Objectives 
The concept of mimicking B7H6 tumor surface expression with short, synthetic 
immunostimulatory peptide ligands alongside tumor cell targeting sequences were conceived to 
develop novel cancer-targeted immunostimulatory peptides (CTIPs) for the purpose of cancer 
immunotherapy. In this dissertation, the rational design, synthesis and biological evaluation of 
CTIPs derived from the immunostimulatory domain of B7H6 and the GRP78 targeting domain on 
tumor cells are presented (Figure 1.9). In this manner, the CTIPs are anticipated to target cell 
surface expression of GRP78 on tumors while recruiting and activating NK cell immunotoxicity. 
Significantly, the CTIPs are not only expected to enhance cancer immunotherapy effects but also 
provides insight into the development of synthetic antibody mimics and peptide vaccines.  
 
 
Figure 1.9. Rational design and cancer immunotherapy applications of CTIPs. 
 
In Chapter 2 of this thesis, a detailed analysis of the work accomplished by my colleague 
Keith Smith, M.Sc. while working in the labs of Drs. Bitsaktsis and Sabatino at Seton Hall 
University and reported within his M.Sc. thesis are provided.25 The research objectives of this 
study included the preparation of a library of synthetic peptides incorporating the NKp30-binding 
motif (TVPLN) derived from B7H6 that functions to activate NK cells along with GRP78-
targeting motifs (WIFPWIQL, RLLDTNRPFLFY and CTVALPGGYVRVC) that bind to tumor 
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cells. The implementation of Fmoc-based solid phase synthesis (Fmoc-SPPS) allows for the 
construction of the desired peptide sequences on solid phase. In this synthesis strategy, the 
synthetic peptides will be designed and constructed as Y-shape antibody mimics. The first step 
involves synthesis of the NKp30-binding motif (TVPLN) as linear dimers separated by a suitable 
spacer in order to enable synthetic efficiency and modularity. The GRP78-targeting peptides will 
be introduced within the spacer position to yield the Y-shape trimeric CTIPs. Sample analysis and 
characterization will be accomplished by tandem liquid chromatography mass spectrometry 
(LCMS) which will be used to ascertain peptide purities and identities. Peptide analysis by UV-
Vis spectroscopy will also be implemented to confirm chromophore presentation, including the 
incorporation of fluorescein isothiocyanate (FITC) as fluorescent reporter. Moreover, peptide 
analysis by UV-Vis spectroscopy will be used to determine sample concentration in aqueous media 
for biological and immunological evaluation.    
In Chapter 3 of this thesis, my contributions will be highlighted with cell line culture and 
testing of peptide samples in biological and immunological assays along with data acquisition and 
processing. This work and the translation of cell line to in vivo testing will also be supported by 
the research group of Dr. Robert Korngold at the Center for Discovery Innovation, Hackensack 
UMC in Nutley NJ. In this thesis chapter, the synthetic peptide will be initially screened for their 
binding capabilities to the target tumor cells (HepG2 and A549 cells) and the NK92-MI cell line. 
Moreover, a series of blocking and displacement assays will be developed to determine tumor cell 
line GRP78 and NK92-MI cell line NKp30 receptor binding specificities against competing 
peptide ligands and antibodies. The synthetic peptide library will also be screened by Luminex to 
determine the capabilities (if any) for the synthetic peptides to secrete inflammatory cytokines 
such as TNF and IFN from the NK92-MI cell line. Following the biological and immunological 
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screening assays, a lead trimeric peptide will be selected for exhibiting NKp30 binding and 
activating as well as GRP78 targeting on tumors for promising cell-binding and 
immunostimulatory responses. Peptide activity will then be monitored in co-culture, in order to 
evaluate the capabilities for peptide i) targeting and binding to GRP78+ tumor cells, while ii) 
targeting and activating NK cells in an NKp30 dependent manner, in order to iii) elicit 
immunotoxicity responses that can be monitored by, iv) the secretion of pro-inflammatory 
cytokines/chemokines and v) tumor cell death. Following our in vitro analysis, a lead peptide will 
be administered with and without the NK cells and examined in immunodeficient NSG (NOD.Cg-
Prkdc(scid)ll2rg/Szj, NOD SCID mice) mice challenged with tumor cells to evaluate its 
immunocytotoxicity effects in vivo. Tumor growth as a function of time was monitored to explore 
the in vivo treatment efficacy of our peptide-NK92 MI cell line formulation.  
In Chapter 4 of this thesis, a summary of the most important contributions to knowledge 
will be presented as well as a perspective of current and future work that can be based on this 
proof-of-concept study. In sum, my thesis will present a collaborative, multidisciplinary effort in 
between the Bitsaktsis (Department of Biological Sciences, Seton Hall University), Sabatino 
(Department of Chemistry and Biochemistry, Seton Hall University) and Korngold (Center for 
Discovery, Hackensack UMC) groups in cancer immunotherapy. The NIH/NCI grant 
(1R03CA216136-01) is specifically acknowledged for providing funding support for this work. A 
manuscript (cbic.202000407based on this work is currently under review in the ChemBioChem. 
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Chapter 2: Synthesis of Cancer-Targeting Immunostimulatory Peptides 
 
2.1 General Introduction to Solid Phase Peptide Synthesis 
2.1.1 FMOC and BOC Solid Phase Peptide Synthesis Strategies 
Synthetic peptides have improved characteristics relative to their native peptide 
counterparts including high bioactivity, high specificity and low toxicity making them attractive 
therapeutic targets.1  They can be generated by three general methods including: i) synthesis in-
solution, ii) on solid support, ii) or in combination approaches featuring tandem solid and solution-
phase synthesis.1 Of these methods, the solution-phase peptide synthesis method was the preferred 
method by pharmaceutical companies in the 1970s.1 In this method, the amino group of the 
coupling amino acid must be orthogonal protected while the carboxyl group is activated by 
carbodiimides such as N,N’-dicyclohexylcarbodiimide (DCC) or 1,3-diisopropylcarbodiimide 
(DIC) coupling conditions results in peptide bond formation (Figure 2.1).1 
 
 
Figure 2.1. Carbodiimide-based peptide coupling reactions in-solution.1  
 
Today, peptide synthesis is often performed by the solid-phase peptide synthesis (SPPS) 
method.1 Each amino acid in the peptide sequence is sequentially bound to the following while 
attached to the polymer-based solid support or resin.1 The peptide synthesis method includes 
 35 
repeating activation, coupling and deprotection steps in which soluble reagents react with the resin 
beads (Figure 2.2). Once the sequence is complete, the peptide is separated from the resin and any 
latent protecting groups removed during the cleavage and deprotection step.1 In contrast to 
solution-phase synthesis methods, no significant loss in peptide recovery results from washing or 
filtration of the insoluble resin while circumventing the need for stepwise work-up or purification 
steps.1 In this manner, peptide loss is prevented since all reactions are carried out in a single 
reaction vessel.1 In the hybrid synthesis, or combination of solution and SPPS, peptide synthesis 
occurs by SPPS and then is completed by condensation from a solution of two or more suitable 
peptide sequences.1 This method is commonly applied to conjugation or ligation strategies for the 
introduction of chemical and biological probes that may improve peptide activity.2  
 
 
Figure 2.2. Solid phase peptide synthesis strategy.1 
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There are two main strategies of SPPS including Boc and Fmoc chemistry.1 In the Boc 
approach, harsh acids such as HF are required for peptide cleavage from the solid support making 
it difficult to accomplish in a traditional lab setting.1 However, HF is not required in the Fmoc 
method, making the Fmoc-SPPS the desirable method of use today.1 Boc synthesis uses strong 
acids such as anhydrous hydrofluoric acid (HF), trifluoromethanesulfonic acid (TFMSA) or 
trimethylsilyl trifluoromethanesulfonate (TMSOTf) for cleavage.1 In Boc-SPPS synthesis method 
(Scheme 2.1), the C-terminal amino acid is anchored to the support via formation of a benzyl ester 
with a suitably functionalized solid support, such as the hydroxymethylphenylacetamidomethyl 
polystyrene (PAM resin) and the tert-butoxycarbonyl (Boc) is used for protection of the alpha-
amino group.3 The Boc group is removed with neat trifluoroacetic (TFA) in dichloromethane 
(DCM). Diisopropylethylamine (DIPEA) in DCM is used prior to coupling for neutralization of 
any latent trifluoroacetic acid/acetate reagent and also serves as a carboxylic acid activating 
reagent during the coupling reaction.3 Originally, activation of incoming amino acids with 
dicyclohexylcarbodiimide (DCC) in DCM resulted in coupling.3 However, the preferred method 
today uses pre-formed amino acid symmetrical anhydrides or benzotriazolyl esters in DMF or N-
methylpyrrolidone (NMP) as suitable solvent conditions.3 Benzyl-based protecting groups that 
substitute the benzyl ring of functional groups with either electron donating or withdrawing groups 
have been developed to mask side-chains of amino acids.3 Anhydrous hydrogen fluoride is used 
for the release of the peptide from the resin and the removal of the side-chain protecting groups.3 
The Boc method is remarkably efficient in the synthesis of large peptides and small proteins.3 
However, HF in a polytetrafluoroethylene (PTFE)-lined apparatus is highly toxic limiting the 
widespread use of this methodology.3  
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Scheme 2.1. Boc-SPPS strategy.3 
 
The Fmoc/tBu method is based on an orthogonal protecting group strategy using the base-
labile N-Fmoc group for protection of the alpha-amino group and acid-labile side-chain protecting 
groups and resin-linkers for peptide removal from the solid support.3 In the Fmoc-SPPS method 
(Scheme 2.2), side-chain protecting groups and linkers are removed under milder acidic conditions 
(i.e. TFA) compared to the Boc method (i.e. HF) making this method much more practical for 
general lab use.3 This includes the removal of t-butyl- and trityl-based side-chain protecting groups 
and alkoxybenzylether-based linkers from the solid support using TFA.3 TFA is an excellent 
reagent for peptide synthesis as it can be easily implemented in standard laboratory glassware, 
provides good resin swelling which increases peptide yields from the solid support and has a 
volatile characteristic making it readily removed by evaporation.3 In the Fmoc/tBu approach, the 
C-terminal residue is anchored to a TFA-labile linker, such as the commonly used Rink linkers or 
 38 
Wang resins for respectively generating peptide amides or acids. TFA-labile protecting groups 
(e.g. tBu/trityl) are used to protect the side-chain functionalities and can be concomitantly removed 
during the final peptide cleavage step from the solid support.3 The orthogonal N-Fmoc protecting 
group is base-labile removed with 20% piperidine in DMF. Coupling occurs with pre-formed 
active esters or activation reagents that generate in situ benzotriazolyl esters in DMF or NMP.3 
Peptide cleavage from the resin and side-chain deprotection is accomplished with 95% TFA, with 
the remaining quantity being scavenger reagents (e.g. H2O, TES or TIPS) used to neutralize 
reactive intermediates generated during peptide cleavage and deprotection steps.3 
 
 
Scheme 2.2. Fmoc-SPPS strategy.3 
 
2.1.2 Resins used for FMOC Solid Phase Peptide Synthesis 
The resin used in SPPS is a spherical polymer bead with reactive groups that the first amino 
acid of the sequence will attach to.1 This support must not be disrupted by mechanical mixing, 
temperature changes or the use of different solvents and must have a narrow range of bead pore 
sizes and loading of reactive functional groups, typically amines.1 Likewise, the resin must have 
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high swelling properties in organic solvent to maximize the contact surface area in between the 
reactive groups on the amino acid and the solid support. Suitable resins for SPPS are able to swell 
up to 5-6 times in dichloromethane (DCM) or dimethylformamide (DMF).1 In general, resin solid 
supports range in size from 100-200 mesh or 200-400 mesh.1 The most common classes of 
synthetic, polymer-based resins include: i) the polystyrene (PS) resins that are crosslinked with 
1% divinylbenzene (DVB), ii) the PS-functionalized polyethylene glycol (PEG) resins, iii) the pure 
cross-linked PEG resins and iv) polystyrene cross-linked with 1,6-hexanediol diacrylate (PS-
HDODA) resin (Figure 2.3).1,4 Resins may also be pre-loaded or loaded with start amino acid or 
short peptide sequences for facilitating peptide synthesis of more difficult sequences. Pre-loaded 
resins may either have a low or high loading capacity (i.e. mmol of peptide per gram of resin) such 
that when highly loaded resins are used, aggregation of the peptide sequences increases and may 
lead to amino acid deletions or poor peptide synthesis efficiencies.1 Therefore, low loading 
capacity polar PEG-based resins that are pre-loaded with the first amino acid are the most common 
in the synthesis of challenging peptides that are prone to aggregation.1,5,6 
 
 
Figure 2.3. Synthetic polymers used for solid-phase peptide synthesis. 
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 The two common procedures for peptide synthesis include batchwise and continuous-flow 
that differ in the washing of the resin between synthetic steps.3,7 The batchwise process uses 
peptidyl resin that is contained within a fritted reaction vessel.3 Here, reagents are added portion-
wise through the top of the vessel and removed by the application or positive nitrogen pressure or 
vacuum.3 The resin is commonly composed of 1% divinylbenzene cross-linked polystyrene (PS).3 
PS is inexpensive to produce, swells in the common solvents used for peptide synthesis such as 
DCM, DMF and NMP and is readily functionalized via the Friedel-Crafts reaction with 
chloromethyl, aminomethyl and benzhydrylamino groups.3 
The continuous-flow method uses a resin packed into a column.3 Here, solvent is pumped 
through the resin bed to wash the solid support during peptide synthesis.3 Polystyrene-based resins 
are also most commonly used for this type of synthesis if the resin is co-packed with glass beads 
or when low flow rates are used.3 However, the use of glass beads or low flow rates may disrupt 
synthesis.3 Supports manufactured for this purpose include the Macrosorb, NovaSyn K or 
Polyhipe resins.3 However, these materials are friable, degrade over the course of long 
assemblies and are not always packed evenly that may disrupt reagents passing through the resin 
bed.3 
The polyethylene glycol (PEG) materials have surpassed all other supports over the years.3 
These supports include Tentagel and polyethylene oxide-polystyrene (PEO-PS) that are prepared 
by grafting PEG to low cross-linked polystyrene.3 These supports can be used in both batchwise 
and continuous-flow synthesis.3 They are spherical, able to withstand high back-pressures and are 
packed well into the reaction columns.3 PEGA and CLEAR are newer supports with cross-linked 
PEG that possess similar functionality to the PEG-PS supports.3,8–10 
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Linkers or chemical spacers containing reactive functional groups are required to connect 
the first amino acid to the resin.1 The theoretical yield of a peptide and the amount of reagents 
required for peptide synthesis are determined by the number of reactive groups on the linker that 
is loaded onto the resin.1 Lower linker loadings on solid support improves synthesis efficiencies 
but lower yields, whereas, higher linker loadings may provide more peptide material at the end of 
synthesis but with an overall lower quality that necessitates purification. Linkers are also designed 
to release peptide acids or amides when treated with TFA.3 Peptides may be released in a fully 
deprotected form or still retaining the acid-sensitive side-chain protecting groups depending on the 
concentration of TFA used and the type of linker.3 Nucleophiles that are used for the preparation 
of C-terminally modified peptides also include hydroxides (OH-), hydrazines (NH2NH2) and 
hydroxylamines (NH2OH). Fmoc/tBu SPPS commonly uses Wang resin, 4-
hydroxymethylphenoxy acetyl (e.g. NovaSyn TGA resin), 4-(4-hydroxylmethyl-3-
methoxyphenoxy)butyryl (HMPB), 2-chlorotrityl chloride resin, SASRIN resin, 5-(4-
hydroxylmethyl-3,5-dimethoxyphenoxy)valeryl (HAL) and the chlorotrityl resin that can all be 
used to generate a C-terminal peptide acid with varying concentrations of TFA that can be used to 
effect the presence of the side chain protecting groups and/or peptide bound support. , The Rink 
amide resin , 5-(4-N-Fmoc-aminomethyl-3,5-dimethoxyphenoxy)valeryl (PAL) resin, Sieber 
amide resin have all been implemented for generating C-terminal peptide amide modifications. 
Further, the 4-hydroxymethyl benzoyl resin has been implemented for generating either-terminal 
peptide acids, hydrazides, amides, esters or alcohols, depending on the chemical nature of the 
nucleophile used for peptide cleavage from the solid support. Furthermore, 3-nitro-4-
hydroxymethyl benzoyl resin has also been used to generate C-terminal peptide acids, hydrazides, 
amides, esters or alcohols, while thes, 3-carboxypropanesulphoamide (Ellman’s ‘safety-catch’ 
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linker), 3-nitro-4-N-Fmoc-aminomethyl benzoyl, and alpha-methyl-6-nitro-veratrylamine have all 
been used as functionalized linkers for developing new chemistry at the peptide C-terminal 
modification.3 
 
2.1.3 Coupling Reagents and Conditions for Peptide Synthesis 
Peptide linkage requires the reaction between an activated carboxylic group of one amino 
acid and the amino group of another amino acid.1 The remaining functional groups of each amino 
acid must be protected orthogonally to prevent side reactions from occurring.1 Many protecting 
groups are used that vary according to the amino acid and methodology (i.e. Fmoc or Boc 
synthesis).1 The chemical nature of the protecting group is determined by the reactive nature of 
the amino acid side chain.1,11 Amino acids often have side chains that contain reactive functional 
groups. Therefore, the side-chains are protected to mask them from side reactions that can occur 
during the course of peptide synthesis and to achieve the highest level of efficiency.3 Protecting 
groups that are removed with TFA are recommended since this allows the peptide to be deprotected 
at the same time it is cleaved from the solid support.3 Moreover, the amino acid N-terminus is 
blocked with the base-labile Fmoc protecting group for the preferred Fmoc/tBu SPPS method. 
This protecting group strategy allows for selective activation and coupling of the amino acid C-
terminus with the (pre-loaded) resin. Commonly used activators and coupling reagents for SPPS 
include: BOP that generates a water-soluble product and is useful for solution phase synthesis, 
COMU is highly reactive and superior for hindered couplings, DEPBT is useful for coupling of 
protected fragments with low racemization, HATU is ideal for hindered couplings, HBTU that is 
an excellent reagent for routine synthesis, HCTU that is more reactive than HBTU and HATU, 
PyBOP  is excellent for routine synthesis and ideal for in situ activation, PyAOP is also ideal for 
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hindered couplings, fragment condensation and peptide cyclization, PyOxim is similar to PyBOP 
but generates a reactive active species and TSTU is useful for the coupling of dyes/PEG reagents 
in water.12 
 In the conventional Fmoc/tBu SPPS method (Figure 2.2), peptide synthesis begins by 
attaching the resin linker with the C-terminal amino acid using a suitably selected coupling 
reagent.3 This step determines the yield of the final product and, if performed inadequately, can 
lead to acylation in sites not reacted in this initial phase that result in C-terminally truncated by-
products.3 Some resins have a hydroxyl group anchorage point.3 This linkage can be accompanied 
by racemization, a serious problem with histidine and cysteine.3 Peptides containing proline or N-
alkylated amino acids in the C-terminal dipeptide sequence have a greater risk of cyclizing to 
diketopiperazine.3 This results in reduced yield of the desired product and leads to truncated 
sequences. Supports in which the dipeptide is anchored by benzyl ester generate this side-reaction.3 
In order to limit these side reactions, advancements in peptide synthesis such as the choice of 
solvent that determines the peptide-resin swelling and thereby influences reactive site accessibility 
as well as affecting the kinetics of the coupling reaction. Other advancements include the use of 
potent coupling reagents such as HATU or active FMOC amino acid derivatives such as acid 
fluorides to drive coupling to completion.3 
SPPS uses treatment with 20-50% piperidine in DMF to remove the N-Fmoc group.3 The 
fluorene ring is initially deprotonated to generate an aromatic cyclopentadiene-type intermediate 
that rapidly eliminates to form dibenzofulvene that is then scavenged by piperidine (Figure 2.4).3 
The deprotection reaction products readily absorb UV light at 280 nm in order to monitor reaction 
conversion and to also quantitate peptide loading on the solid support.3 Continuous-flow peptide 
synthesizers monitor synthesis by following the change in optical density of the column effluent 
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with time whereas monitoring of the deprotection reaction is carried out by taking aliquots and 
measuring the change over time of the optical density of the sample in batchwise synthesizers.3 
 
 
Figure 2.4. Fmoc deprotection mechanism.3 
 
Cleavage of a peptide from the solid support occurs by exposing the resin to a reactive 
cocktail that facilitates selective removal of the peptide from the solid support without unwanted 
side reactions.1 The appropriate reagents and reaction conditions must be selected to prevent the 
peptide from  irreversibly being modified or damaged.1 An important step is to wash the peptide-
bound resin with DCM prior to cleavage to remove all DMF since it can inhibit TFA acidolysis.1 
During cleavage, the synthesized peptide sequence is removed from the resin and the amino acid 
side-chain protecting groups are removed in a single-batch reaction.1 As mentioned, Boc synthesis 
uses strong acids such as anhydrous HF, TFMSA or TMSOTf for cleavage while Fmoc synthesis 
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uses cocktails containing TFA for cleavage.1 Peptide-bound resins are typically treated with 95% 
TFA and gentle shaking for 1-3 hours.1 Scavengers such as EDT, TES, TIPS, phenol and 
thioanisole are added into the cleavage cocktail to prevent cationic side-products from reacting 
with the electron-rich side chains of amino acids such as Trp, Tyr and Met (Figure 2.5).1 Scavenger 
types and amounts are decided by the type of amino acids involved in the resin-bound peptide 
sequence.1 For instance, EDT protects Trp against oxidation and should be used when there is one 
or more Trp in the peptide sequence.1 
 
 
Figure 2.5. Scavenger activity during the peptide cleavage and deprotection step.1 
 
2.1.4 Bioconjugation Techniques 
 Bioconjugation is the attachment of molecular probes to biological molecules usually 
through covalent bonding in order to enhance the activity of the parent bio-molecule.13 New 
synthetic complexes with improved properties are generated from bioconjugates in a manner that 
renders them much more useful in studying naturally occurring processes.13 An example of this is 
the attachment of a fluorescent label (i.e. fluorophore) to an antibody to create an antigen targeting 
complex that can be monitored by fluorescence detection intracellularly or even within in vivo 
models.13 The process of bioconjugation typically occurs in a series of reactive crosslinking steps 
and often coupling reactions are performed using secondary activating agents.13 Using the proper 
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crosslinking reagents is key to successful bioconjugation. Bioconjugates may be constructed with 
multifunctional components.13 For instance, molecules may contain one or more reactive 
functional groups that can be used to ligate  multiple probes or other biomolecules with specific 
activity.13 Conjugates can also contain small ligands that interact with other proteins directly.13 
One example is biotin that interacts with (strept)avidin reagents.13 This interaction is strong and 
allows for highly specific interactions to occur with the biotinylated conjugate.13 
 Of specific interest and relevance to this study are the peptide-based bioconjugates that can 
be generated synthetically to improve the biological and therapeutic properties of the native 
peptide sequence.14 Bioconjugation techniques with peptides have been directly implemented 
within the peptide sequence, as the peptide N- and C-termini as well as the amino acid side chain 
groups all provide reactive functional groups that can be used for the incorporation of the 
bioconjugate. Additionally, synthetic linkers, spacers and modifiers have been incorporated within 
the peptide sequence as an indirect point of attachment for the bioconjugate.15 In these cases, the 
peptide sequence is separated from the bioconjugate in order to maintain the structure-activity 
profiles of the native peptide. A variety of synthetic strategies have been developed for the 
incorporation of peptide bioconjugates.16 Among the most ubiquitous are the conjugation 
strategies for the incorporation of a fluorescence probe such as fluorescein isothiocynate (FITC) 
for studying peptide biology and immunology.13,17 FITC is one of the most popular probes with an 
absorbance wavelength at 495 nm and emission wavelength of 520 nm which facilitates sample 
detection in the (green) visible region.13 Isothiocyanates react with amines, sulfhydryls, and the 
phenolate ion of tyrosine side chains, but stable products are generated with the primary amine 
group (Scheme 2.3).13 This conjugation reaction involves nucleophile attack on the central, 
electrophilic carbon of the isothiocyanate group.13 An electron shift occurs that creates a thiourea 
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linkage between FITC and the peptide/protein without a leaving group.13 The stable fluorescein-
linked peptides have enabled a wide range of applications, including tracking cell targeting/binding 
and uptake activity, intracellular trafficking and localization for biological activity.18 
 
 
Scheme 2.3. Synthetic strategy for the incorporation of FITC within a peptide sequence.3 
 
2.2 Analysis and Characterization of Synthetic Peptides 
2.2.1 Reverse-Phase HPLC 
Reverse-phase HPLC (RP-HPLC) is a technique used for the separation and analysis of 
peptides and proteins.19 The biotechnology industry largely uses RP-HPLC to isolate therapeutic 
peptides and optimize the purities of these products.19 Separation of peptides from digested 
proteomes prior to identification by mass spectrometry is accomplished by RP-HPLC.19 RP-HPLC 
is versatile, with sensitive detection, can be used together with other techniques including mass 
spectrometry and is able to separate peptides of nearly identical structure as in the case of human 
and porcine insulin variants.19 These insulin variants differ by three amino acids yet are well 
separated by RP-HPLC.19 
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The silica-based particle surface of the stationary phase in RP-HPLC columns is 
hydrophobic as a result of the chemical attachment of hydrocarbon groups.19 The hydrophobic 
surface of particles packed in the columns are usually composed of silica since this is physically 
robust and stable under most solvent conditions while amenable to different spherical particles of 
various pore sizes with different diameters.19 The hydrophobic surface, termed the hydrophobic 
foot, is composed of varying lengths (C3-C18) of hydrocarbon chains that retains peptides by 
adsorbing a portion of the protein to the hydrophobic surface via non-polar interactions.19 
Considering peptides contain polar groups and can be hydrophilic in polar solvents, this leaves the 
majority of the peptide to interact with the mobile phase. The hydrophobic adsorption results in a 
very strong net interaction that allows the peptide to remain adsorbed to the surface until a specific 
concentration of organic solvent is reached. Once this concentration is reached, the peptide will 
desorb from the surface and elute from the column.19 Separation is based on the single 
adsorption/desorption process from the stationary phase and into the mobile phase for each 
individual peptide component in the mixture. The sharp peaks seen within RP-HPLC 
chromatograms are the result of peptide retention changing abruptly once the desired concentration 
of organic solvent is reached.19 This signal is typically detected based on the UV absorption of the 
peptide at 220 nm (peptide bond), 254 nm (Phe) and 280 nm (Tyr and Trp) monitored according 
to its retention time (min). The peptide retention time will vary from smaller molecules (less 
retained) to larger ones (more retained) on the stationary phase. Isocratic elution (single mobile 
phase concentration) is seldom useful with peptide separation, making gradient elution (varying 
mobile phase concertation) the most commonly used method for sample purification.19 
Separation performance is widely dependent on the purity of silica in the HPLC column. 
Peak tailing and loss of resolution occurs from metal ion impurities.19 These silica columns then 
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require high concentrations of an ion-pair reagent such as TFA or formic acid (FA) to maintain 
good peak shape while low concentrations of TFA will result in poor peak shape and resolution 
loss.19 Silica columns that are pure may require concentrations of TFA or FA as low as 0.005% 
and result in good peptide resolution.19 This is important since low concentrations of TFA or FA 
results in better LC-MS signal detection since TFA causes signal reduction in the electrospray 
interface.19 Other commonly used reagents in RP HPLC separation include phosphoric acid and 
heptafluorobutyric acid (HFBA).19 Phosphoric acid is generally used to separate peptides that are 
not separated by TFA or FA.19 Phosphate buffers are also used to offer better separations than TFA 
at a concentration between 20-30 mM.19 However, phosphate buffers are not volatile and therefore 
difficult to remove from the peptide. HFBA is used for the separation of proteins such as histones.19 
RP-HPLC columns prefer wide pore silica (~300 angstrom diameter) to provide an ideal 
separation of peptides.19 Larger peptides have difficulty entering the small pores leaving only a 
small exterior surface for separation.19 Wide pore silica allows large peptides to enter the pore and 
interact with the surface fully thereby attributing to better peak shape and resolution.19 Today, wide 
pore silicas are used for peptide and protein separations.19 Different peptide selectivity occurs for 
different RP columns including the amount of phase, referred to as the carbon load, of the silica 
that affects selectivity and the different manufacturing processes that generate silica with different 
properties.19 Lower carbon load (i.e. C3 columns) indicates less hydrocarbon attached to the 
surface.19 Here, polar silanols may affect the separation to a greater extent when compared to 
higher carbon load (i.e. C18) columns.19 Column dimensions also play an important role in peptide 
separation. Longer columns tend to give better resolution than short columns since better 
resolution is achieved with greater particle interactions with the column surface.19 The standard 
diameter of an analytical HPLC column is 4.6 mm and runs best at a flow rate of ~1 mL/min.19 
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Narrow bore columns run at flow rates of ~200 L/min and exhibit about five times the sensitivity 
of standard analytical columns because the amount of solvent is much lower and therefore a higher 
concentration of peptide is separated.19 Microbore columns run at flow rates of ~50 L/min with 
even better sensitivity while capillary columns run at about 1 – 50 L/min and the highest 
sensitivity.19  
 
2.2.2 Mass Spectrometry 
Mass spectrometry (MS) is an analytical technique used to determine the mass and 
sequence characterization of biomolecules including proteins and peptides.20 The workflow for 
MS-based peptide/protein characterization technique is similar in three distinct stages.20 Peptides 
or proteins are initially isolated from their biological source, digested and the peptide is 
fractioned.20 The fractioned peptides are then analyzed by qualitative and quantitative mass 
spectroscopy.20 This generates large data sets that can be analyzed by software tools to determine 
the amino acid sequence and quantity of peptides/proteins in the sample.20 Shotgun proteomics is 
used to analyze complex peptide mixtures. In this application, the resulting peptides samples are 
extensively fractionated and then analyzed by automated MS/MS which provides important 
sequencing information.20 Usually, rapidly scanning analyzers such as ion trap mass spectrometers 
are used.20 
 Mass spectrometers measure the molecular mass of a polypeptide or determine additional 
structural features such as the incorporation of modified amino acids or the type and site of 
attachment for many types of posttranslational modifications.20 Single-stage mass spectrometers 
are used to measure the molecular mass of a polypeptides.20 Tandem mass spectrometry (MS/MS) 
is used to determine the amino acid sequence or posttranslational modifications.20 Here, mass is 
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measured and then specific ions are selected and undergo collision to generate fragments.20 The 
structural features of peptides are then inferred from the analysis of the fragment masses.20  
In the late 1980s two MS techniques were developed including electrospray ionization 
(ESI) and matrix-assisted laser desorption/ionization (MALDI).20 Before this development, MS 
was only used to analyze small compounds that were thermostable.20 ESI and MALDI made 
possible the analysis of polypeptides.20 With these techniques, new mass analyzers and multistage 
instruments were developed including the hybrid quadrupole time-of-flight (Q-Q-ToF) and tandem 
time-of-flight (ToF-ToF) instruments.20 Time-of-flight instruments measure the mass-to-charge 
ratio of an analyte by determining the flight time of the analyte through a vacuum-subjected tube 
for a specified length.20 These analyzers are the basis for the analytical platforms of ESI and 
MALDI.20 The Q-Q-ToF instruments have high resolution and mass accuracy in MS and MS/MS 
mode and are considered high resolution instruments for exact mass detection.20 In the MS mode, 
mass analysis takes place in the ToF analyzer after a quadrupole guides the ion to the ToF 
analyzer.20 In the MS/MS mode, precursor ions are selected in the first quadrupole and fragmented 
via collision-induced dissociation in the second quadrupole.20 The ToF analyzer then assess the 
ions.20 MALDI MS is sensitive and more tolerant than ESI to contaminations by salts or relative 
detergents. MALDI is typically used with ToF analyzers to measure molecular mass with a high 
degree of certainty.20 
Ion trap (IT) mass analyzers allows high-throughput analyses by trapping ions such that 
the ions accumulate over time in a physical device.20 However, IT analyzers are limited in their 
resolution and ion trapping capacity such that the development of linear ion trap (LIT) analyzers 
resolved with higher ion-trapping capacities.20 The LIT instruments possess multiple-stage 
 52 
sequential MS/MS functions that allow fragment ions to be isolated and further fragmented which 
is useful in the analysis of posttranslational modification such as phosphorylation.20 
   
2.2.3 Ultraviolet-Visible (UV-Vis) Spectrophotometry 
Ultraviolet-Visible (UV-Vis)  spectrophotometry allows for rapid detection of inorganic 
and organic substances.21 UV-Vis spectrophotometry is a routine analytical technique used to 
quantitate different analytes such as transition metal ions, highly conjugated organic compounds 
and biological macromolecules.21 The technique utilizes the absorption spectra generated from 
electron transitions between energy states in a molecule.21 These transitions are accompanied by 
absorption of a quantum of energy in the UV-Vis (190 – 800 nm) region.21 UV or visible light 
energy is absorbed by molecules with bonding and non-bonding electrons, an energy absorption 
that then excites the electrons to higher anti-bonding molecular orbitals.21 In general, electrons that 
are more easily excited such as those with lower energy gaps between the highest occupied 
molecular orbital (HOMO) and the lowest occupied molecular orbital (LUMO), will have longer 
wavelength of light to absorb.21  
 The spectrophotometer directly measures the intensity of light after passing through a 
sample and compares this intensity of light before it passes through the sample to generate the 
transmittance (I/Io).21 Absorbance is then determined by A= -log (I/Io).21 The spectrophotometer 
is composed of a light source, a sample holding area, a detector and a prism that separates the 
different wavelengths of light.21 The detector is a photomultiplier tube, a photodiode, a photodiode 
array or a charge-coupled device (CCD).21 Single photodiode detectors and photomultiplier tubes 
are used with scanning monochromators in which light of a single wavelength is filtered such that 
it reaches the detector at one time.21 Peptides or proteins typically absorb in the UV region of the 
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electromagnetic spectrum. Some of the key functional group absorptions include the peptide bond 
at 220 nm (amides), 254 nm (Phe) and 280 nm (Tyr and Trp). Since these chromophores typically 
absorb weakly in the UV-Vis spectra, polyaromatic probes, including fluorophores such as FITC 
have also been incorporated for peptide spectral characterization.22 Considering the sample 
absorption is directly correlated to sample concentration according to the Beer-Lambert law (A 
=  * b * c), this analysis provides a quantitative measure of peptide concentrations in solution. 
 
2.3 Chapter Objectives 
In this chapter, the rational design, synthesis and characterization of bifunctional trimeric 
synthetic peptides will be delineated. This work is based on the contributions of Keith Smith, M.Sc. 
as detailed in his thesis22 and Andrieh Darwich B.Sc. that assisted in the synthesis of control, linear 
peptide sequences. The reported trimeric peptides are based upon GRP78-targeting peptides for 
homing into surface GRP78 expressing tumors and the NKp30 activating peptides that can trigger 
NK cell cancer immunotherapy. The synthetic approach will be based on solid-phase peptide 
synthesis for generating a series of trimeric peptides with a single GRP78 binding motif emanating 
from a branching lysine side chain and two NKp30 binding and activating motifs spanning the N- 
and C-terminal regions of the peptide main chain (Figure 2.6). Following peptide synthesis, the 
samples will be purified by RP-HPLC and characterized by LCMS and UV-Vis spectroscopy. 
With purified peptide in hand, a structure-activity relationship study may be explored to determine 
the targeting and effector functions of the bifunctional trimeric peptides.  
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Figure 2.6. General structure of the bifunctional trimeric peptides. 
 
2.4 Rational Design of Synthetic Peptides 
2.4.1 Synthetic and Biological Background Associated with GRP78-Targeting Peptides 
Cancer-targeting peptides (CTPs) are a class of molecules that have the ability to target 
tumor cells by binding to surface receptors with high affinity and specificity. Moreover, CTPs have 
been combined with detection probes and anti-cancer agents for selective cancer detection and 
treatment, an effect termed “theranostic” activity attributed to the therapeutic and diagnostic 
properties of these bifunctional peptides.23 Of specific interest in this study are the CTPs targeting 
the Glucose Regulated Protein of 78 kDa (GRP78). GRP78 is a member of the glucose regulated 
family of chaperone proteins which primarily functions in assisting in protein misfolding events 
occurring in the lumen of the endoplasmic reticulum (ER) as part of the unfolded protein response 
(UPR) mechanism.24 Moreover, GRP78 is a multi-functional regulator of cell homeostasis, 
effecting intracellular signaling events associated with embryonic development, aging, Ca2+ flux 
and insulin/IGF-1 signal transduction as well as cell death events associated with ER and 
mitochondrial stress.25 In cancer, GRP78 is overexpressed and found on the cell surface where it 
functions as a signaling hub for cancer initiation, proliferation, spread and metastasis as well as in 
treatment resistance.26 Thus, GRP78 has been classified as a clinically relevant biological marker 
in the detection and treatment of many different cancer types. Accordingly, peptidic ligands of 
GRP78 selected by phage display biopanning techniques and computational methods have been 
developed and functionalized with fluorescent reporters and quantum dots for tracking selective 
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cancer cell binding as well as for the delivery of chemotherapeutic agents for targeted tumor 
therapy.27–32 These peptide ligands are thus suitable candidates for GRP78-targeting on cancer 
cells known to express cell surface GRP78. 
 
2.4.2 Synthetic and Biological Background Associated with NKp30-Targeting Peptides 
A series of activating NK cell receptors, including the NKp30 receptor which belongs to 
the natural cytotoxicity receptor (NCR) family of immunoglobulin-like transmembrane proteins 
have been found to be directly implicated in NK cells’ activation and immunostimulatory 
activity.33 A combination of structural and molecular cell biology as well as proteomics revealed 
B7H6 as the activating protein ligand of the NKp30 receptor.34 Importantly, B7H6 is expressed on 
the surface of tumors but not on healthy cells, thereby functioning as a tumor associated antigen 
for activating NK-dependent immunity against B7H6+ tumor cell lines.34 However, the 
downregulation or shedding of B7H6 from the surface of tumor cells results in tumor evasion of 
immunosurveillance and resistance towards NK cell immunotoxicity.35,36 Therefore, new B7H6 
ligands that may effectively target NKp30 and activate NK cells towards the resilient B7H6- 
tumors may lead to more effective NK-dependent immunotherapy. Towards this goal, 
topographical mapping and molecular modeling of the B7H6:NKp30 binding domain revealed the 
binding amino acid residues responsible for ligand-receptor binding interactions.7 These consensus 
residues provided sequence information for the development of new B7H6-derived peptidic 
ligands. Among the series, a pentapeptide TVPLN based on the binding site FG loop region of 
B7H6 displayed a stable -turn geometry based on molecular docking and CD spectroscopy which 
contributed to NK cell binding in an NKp30-dependent manner.37 The peptide also resulted in NK 
cells’ immunostimulatory activity by the secretion of TNF. Thus, the TVPLN peptide may prove 
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to be a promising lead candidate in the development of NK cell immunostimulatory peptides, 
especially against B7H6- tumors.  
 
2.4.3 Rationale for Combining GRP78-Targeting Peptides with NKp30-Targeting Peptides 
We designed a series of peptides with single, variable GRP78-binding motifs28–32 and two 
NKp30-binding motifs (TVPLN)37 that would span the peptide main chain, while being separated 
by a short Gly-Lys-Gly (GKG) spacer, in which K was assigned as the branching residue for the 
incorporation of the GRP78-targeting peptides (Figure 2.6). In this manner, the branch bifunctional 
trimeric peptides were designed to recognize GRP78, specifically expressed on the surface of 
cancer cells, and NKp30 on the surface of NK cells. This rational design approach is hypothesized 
to home in the targeted cancer cells into close proximity to the activated NK cells for an 
immunotherapy response. This targeting and effector functionality of the peptides is reminiscent 
of the bifunctional activity of bispecific antibodies and can therefore provide certain insights into 
the design and development of synthetic antibody mimics.   
 
2.5 Solid-Phase Peptide Synthesis Strategy 
A library of peptides (Table 2.1) incorporating NKp30 binding and NK cell activating 
TVPLN peptides were initially constructed as linear dimers separated by a GKG spacer on solid 
phase. The dimers were extended into branching trimeric peptides incorporating the GRP78-
targeting sequences from the -amino group of the internal K residue found within the spacer. The 
synthesis of the bifunctional trimeric peptides was based on conventional Fmoc-based solid phase 
peptide synthesis (Fmoc-SPPS) on a Rink linker poly(ethylene glycol) (PEG) resin known to 
improve the synthesis efficiency of challenging peptide sequences.9 A novel synthetic strategy was 
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developed to generate the Y-shape, bifunctional trimeric peptides (Scheme 2.4). This approach 
was based on the initial Fmoc-SPPS of the NK cell binding and activating TVPLN sequence 
followed by the incorporation of the GKG spacer which includes an orthogonally protected 
Lys(ivDde). This orthogonally protected Lys residue was used as branchpoint synthon to facilitate 
peptide extension separately at the main chain N-terminus and the side chain -amino group. Our 
approach was specific because after the incorporation of Fmoc-Lys(ivDde)-OH, Fmoc 
deprotection using basic piperidine was performed followed by peptide synthesis for the formation 
of the linear dimer sequence incorporating two TVPLN sequences. The peptide was then capped 
(Ac2O) at the N-terminus to prevent side-reactions and the Lys(ivDde) protecting group was 
removed using hydrazine hydrate (NH2NH2-H2O).38 The GRP78 targeting sequence was next 
extended from the liberated Lys side chain -amino group followed by capping (Ac2O) or 
fluorescein isothiocyanate (FITC) labeling of the N-terminus. This synthetic strategy generated the 
Y-shape, bifunctional trimeric peptides containing two NK cell binding and activating domains 
and a single GRP78 binding domain for NK-dependent immunotherapy.  
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Scheme 2.4. Fmoc-SPPS strategy in developing bifunctional, Y-shape trimeric peptides. 
 
2.6 Peptide Analysis and Characterization 
Following cleavage and deprotection, the trimeric peptides were isolated from the resin 
and analyzed by tandem liquid chromatography mass spectrometry (LCMS). LCMS was used to 
confirm peptide purities according to RP HPLC and identities by molecular weight confirmation 
using ESI MS (Table 2.1). The GRP78 and NKp30-targeting trimeric peptides (Table 2.1, peptides 
6-13) were isolated in good crude yields (25-71%) and purities (61-85%) which however 
necessitated sample purification to isolate pure peptides with purities>95% according to RP-
HPLC. ESI-MS confirmed peptide identities according to their respective mass per charge ratios. 
UV-vis spectroscopy enabled sample quantitation in aqueous solution by specifically monitoring 
the absorptions associates with the peptide bond (220 nm) and FITC (450 nm). Representative 
synthetic methods, characterization data, including RP HPLC chromatograms, mass and UV-Vis 
spectra as originally described are located in Keith Smith’s M.Sc. thesis.22 This data has been 
reproduced with permission in this thesis.   
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Table 2.1. Characterization of Synthetic Peptides. 
 
a Crude purity was determined from RP HPLC at 220nm using 2-80% ACN/H2O with 0.1% FA over 25 minutes. 
Peptides with crude purities<95% were subjected to an additional purification step using the aforementioned RP HPLC 
conditions. In these cases, purified peptides were isolated with purities>95%. b Based on resin loading. d Observed 
mass is based on the mass/charge using [M + H+]/Z detected using MS direct injection in positive mode. e Expected 
mass as determined using ChemDraw. f The peptide charge states using positive mode in MS direct injection. g Based 
on RP HPLC at 220nm using 2-80% ACN/H2O with 0.1% FA over 25 minutes. 
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2.7 Method Efficiency and Flexibility 
The conventional Rink amide-linker bound to the hydrophilic poly(ethylene glycol) 
(NovaPEG) based solid support was originally used to generate the GRP78-binding sequences. 
Our initial studies investigated the synthesis efficiency of Pep42, a GRP78-targeting peptide based 
on the cyclic disulfide linked 13-mer sequence, CTVALPGGYVRAC-CONH2 generated by 
Fmoc-SPPS.32 Peptide synthesis efficiency was evaluated on the Rink amide linker polystyrene-
divinylbenzene (PS-DVB) Merrifield resin, the polystyrene-polyethylene glycol (PS-PEG) 
Tentagel resin and the hydrophilic poly(ethylene glycol) (NovaPEG) based solid support. In this 
study, the solid support had a profound impact on peptide synthesis efficiency. Peptide crude 
purities (34-75%) were measured on the Rink Amide linked NovaPEG resin by RP-HPLC, 
whereas the Tentagel resin afforded peptide crude purities (28-92%) and the Merrifield resin with 
(67-95%) crude peptide purities.32 Thus, the NovaPEG (ChemMatrix) resin provided the best 
peptide synthesis efficiency presumably due to the more polar PEG-based support known to favor 
more efficient couplings on solid-phase by expanding the surface area for reaction and minimizing 
aggregation effects of lengthier, hydrophobic sequences.8–10 Synthetic peptides were also isolated 
in good yields (32-67%) and excellent purities (>95%) according to RP-HPLC while sequence 
identities were confirmed by molecular weight analyses using ESI-LCMS, making the NovaPEG 
resin the choice support for our peptide synthesis strategy.  
The peptides were also functionalized with an N-terminal FITC or acetyl group attached to 
an aminohexanoic acid (Ahx) spacer (Table 2.1). The incorporation of the Ahx spacer at the N-
terminus was found to be essential for the incorporation of FITC. In the absence of a suitable 
spacer, direct FITC incorporation at the peptide N-terminus results in elimination of the 
fluorophore-linked amino acid during the acidic conditions related to peptide deprotection and 
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cleavage from the solid support.17 The incorporation of the GKG spacer also proved essential for 
the development of the branched trimeric peptides. This strategy is reminiscent of the 
incorporation of Lys for the generation of branched and hyperbranched peptides incorporating 
multiple antigenic sequences for synthetic peptide vaccine development.39 In our application, an 
orthogonally protected by a Lys(ivDde) residue was incorporated by Fmoc-SPPS while the side 
chain protecting group was then selectively removed by nucleophilic (4% NH2NH2:H2O:DMF) 
conditions.3 Three successive NH2NH2 treatments for 5 min were required for complete ivDde 
removal according to LCMS analysis.22 Functionalization of the reactive -amino group was then 
accomplished using HCTU/NMP as reactive coupling conditions known to effect complete peptide 
coupling reactions in ~20 min40 as monitored by RP-HPLC/MS. These optimized Fmoc-SPPS 
methods were used to furnish branch trimeric peptides (Table 2.1, 5-13) incorporating NKp30 
binding and NK cell-activating domains as linear dimers with the GRP78-targeting sequences 
emanating from the -amino group of an internal branchpoint Lys residue in good yields (25-71%) 
and purities >95% by RP-HPLC, while ESI-MS analyses confirmed sample identities according 
to mass per charge ratios.22 These peptide were thus considered suitable for biological and 
immunological assays discussed in Chapter 3 of this thesis. 
 
2.8 Conclusions 
In this chapter, the design, synthesis and characterization of bifunctional synthetic trimeric 
peptides has been described. These bifunctional trimeric peptides were designed to contain 
GRP78-binding capabilities on the surface of cancer cells while also possessing NKp30 binding 
and effector functions on NK cells. A combination approach was developed by Fmoc-based SPPS 
incorporating the requisite peptide sequences within Y-shape branching peptides. This synthetic 
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method was optimized to generate a small library of synthetic trimeric peptides in good isolated 
yields and purities according to LCMS and UV-Vis spectroscopy. This synthetic methodology is 
thus applicable to the generation of bifunctional peptide libraries that can be used for structure-
activity relationship studies against their biological targets. 
 
2.9 Experimental Section 
2.9.1 Peptide Synthesis 
Peptides were synthesized on either a stepwise manual or semi-automated solid phase 
peptide synthesis on a PSI 200C Peptide Synthesizer (Glen Oaks, NY, USA). Fmoc-amino acids 
(3 equivalents (eq), 0.1 mmol) were coupled on a Rink amide linker poly (ethylene glycol) solid 
support (0.54 mmol/g, 0.1 mmol) for 30 minutes using HCTU (3 eq., 0.1 mmol), NMM (6 eq., 0.1 
mmol) in DMF (4 mL). A 20% piperidine in DMF solution (4 mL) was used for Fmoc 
deprotection, reaction time 20 min. Amino acid couplings and Fmoc deprotections were repeated 
until the desired sequences were completed.  
 For trimeric peptide sequences, 5 – 13, Fmoc-SPPS was initially accomplished as 
previously described to generate the linear NKp30-targeting peptides followed by acetylation 
(Ac2O:pyr:DMF, 50mmol%:50mmol%:4mL) of the N-terminus. Branching from an internal 
Lys(ivDde) residue was accomplished by ivDde deprotection using 4% NH2NH2:DMF (3 x 5 min) 
followed by DMF washing and Fmoc-SPPS from the liberated ε-amino to generate the GRP78-
targeting peptide sequences. The N-terminus was then coupled with an amino hexanoic acid (Ahx) 
linker followed by acetylation or FITC-coupling.  
 The solid support bound peptide was separated (200 mg, 0.05 mmol) for FITC-labeling or 
acetylation at the N-terminus. For FITC-labeling procedures, the resin was swollen in DMF for 1 
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h. A mixture of FITC (1.1 equiv., 0.05 mmol) in pyridine/DMF/DCM (12:7:5 v/v) was prepared 
and added to the reaction vessel for overnight (at least 18 h) reaction on an overhead shaker at 
room temperature (22oC). For N-terminal acetylation, the peptide bound resin (200 mg, 0.05 
mmol) was treated with a solution of Ac2O (472 µL, 0.1 mmol), pyridine (403 µL, 0.1 mmol) in 
DMF (3 mL) and reacted for 30 min. After FITC-labeling or acetylation reaction was completed, 
the resin was washed with DMF (3 x 3 mL), MeOH (3 x 3 mL), and DCM (3 x 3 mL). Peptide 
cleavage and deprotection from the solid support was accomplished using a mixture of 
TFA:TES:H2O, (95:2.5:2.5 v/v/v) for 4 h. Peptide samples were concentrated using a stream of air 
or nitrogen (air if disulfide bridges were expected) to a viscous oil, precipitated with cold Et2O, 
and centrifuged to a white pellet. The supernatant was decanted, and the peptide pellets were 
dissolved in MeCN/H2O for RP-HPLC and MS analyses. 
 
2.9.2 RP-HPLC 
The crude purity of the peptides was determined by Reverse Phase High Performance 
Liquid Chromatography (RP HPLC) using a Waters 2695 Symmetry® C18 column (3.9 x 150 mm, 
5 µm particle size) with a linear binary gradient of 2-80% MeCN/H2O with 0.1% FA over 25 
minutes with a flow rate of 1 mL/min at 25 oC. Peptide detection was accomplished at 220 nm and 
450 nm for FITC-labeled peptides. Peptides were isolated with purities>95%. Peptides with crude 
purities<95% underwent an additional purification step using the same conditions and isolated 
with purities>95%. 
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2.9.3 Mass Spectrometry  
Peptide analyses and characterization were accomplished on an AgilentTM Technologies 
1100 Series MSD instrument with electrospray ionization (ESI) as ion-source, a single quadropole 
mass analyzer and peptide detection in positive mode ionization. Peptide samples were dissolved 
in 50% H2O in acetonitrile or methanol (1 mg/mL) and analyzed by direct injection using an 
Agilent 1100 series HPLC with an isocratic gradient of 50:50 v/v MeCN/H2O with 0.1% FA for 2 
minutes with a flow rate of 0.5 mL/min at 25 oC.  
 
2.9.4 UV-Vis Spectroscopy 
The concentrations of the peptide solutions in water (1 mL) were determined by UV/Vis 
spectrophotometry using an 8452A Photodiode Array Spectrophotometer from Hewlett Packard. 
Sample absorption measurements were collected in quartz cuvettes (1 cm path length) and were 
initially blank corrected followed by sample absorption measurements for each peptide from 190-
700 nm. Peptide concentrations were determined at 214 nm with the  values of peptides calculated 
according to the general formula: 214 = (peptidebond)(npeptidebonds) + Σ (aminoacid(i))(naminoacid(i)).  
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Chapter 3: Preclinical Applications of Cancer Targeting Immunostimulatory 
Peptides 
 
3.1 General Introduction into the Chemical Biology of GRP78 
The glucose-regulated protein 78 (GRP78) or immunoglobulin heavy chain binding protein 
(BiP) is a member of the glucose regulated chaperone proteins.1 GRP78 is localized in the lumen 
of the endoplasmic reticulum (ER) in all eukaryotes and functions as a chaperone protein assisting 
in protein misfolding.1 The sequence composition of GPR78 is composed of 654 amino acid 
residues that participates in the unfolded protein response (UPR) mechanism by chaperoning 
protein folding and assembly and preventing transport of misfolded proteins.1 At the genetic level, 
GRP78 is encoded by the HSPA5 gene located on chromosome 9 and encompasses 4532 
nucleotides.1,2 In humans, there are two genes encoding for GRP78, one functional gene that 
contains eight exons and a pseudogene, or processed gene, that is in a genomic A-T rich region 
and doesn’t contribute to protein expression.1 The protein is water-soluble with small hydrophobic 
patches that are essential for its function and ability to recognize unfolded proteins that are either 
degraded or refolded by a variety of mechanisms.1 
Expression of GRP78 and its cell surface localization is increased under physiological 
and/or pathological conditions that cause ER stress.1,3 Physiological stress conditions are induced 
by reactions such as low glucose availability for metabolism, treatment with reagents that inhibit 
protein glycosylation and folding events, hypoxia, as well as increased levels of reactive oxygen 
species (ROS) or disruption in intercellular calcium storage and flux.1,4 GRP78 also plays an 
important role in regulating cell apoptosis.5 During ER stress, GRP78 overexpression inhibits 
cytochrome c-mediated caspase activation and caspase-mediated cell death thus defining a 
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protective role for GRP78 in preventing ER stress-induced cell death. Intracellular trafficking and 
transport of GRP78 to the cell surface is typically associated with physiological and pathological 
ER stress conditions.1,6 Overexpression of GRP78 can lead to a fraction of the protein escaping 
ER retention and translocating to the cell surface.1 The KDEL motif receptors must be fully 
saturated for GRP78 to escape retention or the KDEL receptors are suppressed such that they 
inhibit GRP78 transport from the ER to the cell surface where it interacts with peripheral 
membrane bound proteins.1,6 
 GRP78 can interact with a variety of naturally occurring ligands and is associated with 
other proteins on the cell surface to function as a multifunctional receptor that plays an essential 
role in cellular signaling, proliferation, migration, invasion, apoptosis, inflammation and 
immunity.1 Likewise, autoantibodies against GRP78 are secreted, such as antibodies for the N-
terminal surface GRP78 (sGRP78) that induces cell proliferation, whereas, C-terminal binding 
GRP78 antibodies induce apoptosis.1,7 sGRP78 has a high affinity to the ligand a2 macroglobulin 
(a2M), a plasma proteinase inhibitor that affects promoting cell proliferation and viability, as well 
as isthim, a 60 kDa protein, that functions as a proapoptotic ligand to induce mitochondrial 
disfunction.1,8 The prostate apoptosis response 4, Par-4, is another ligand for sGRP78 that induces 
apoptosis by ER stress and activation of the FADD/caspase-8/caspase-3 pathway.1 Kringle 5 is a 
plasminogen that binds to sGRP78 to induce apoptosis in dermal microvessel endothelial cells.1 
 
3.1.1 GRP78 Structure and Biology 
The structure of GRP78 is composed of two domains that include an ATP binding domain 
(ADB) (or nucleotide binding domain NBD) at the amino terminal and a substrate binding domain 
(SBD) at the carboxyl-terminal (Figure 3.1).1 GRP78 is mainly localized in the ER of normal cells, 
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which functions as a cellular organelle for protein synthesis and modification as well as an 
intracellular calcium storage.1 During ER stress, GRP78 is also localized into the mitochondria 
where it interacts with pro-apoptotic executors such as cytochrome c to inhibit stress-induced cell 
death.9  
 
Figure 3.1. Structure of GRP78 (https://www.ncbi.nlm.nih.gov/Structure/pdb/3LDN) 
 
Cell surface GRP78 functions as an important receptor in cell signaling, viability and anti-
cancer therapeutic targeting. GRP78 has also been found secreted extracellularly where it interacts 
with circulating ligands including antibodies and cell surface receptors of endothelial cells which 
activates signaling pathways associated with apoptosis and angiogenesis.10 Nuclear GRP78 has 
also been implicated in DNA-crosslinking experiments used to define its anti-apoptotic activity 
during ER stress induction.11 Thus, GRP78 is a multifunctional player in maintaining cell 
homeostasis in a variety of subcellular compartments in response to ER stress (Figure 3.2).12 
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Figure 3.2. Cellular Roles of GRP78.19  
©2007 Lee with permission. 
 
3.1.2 GRP78 Activity in Cell Homeostasis and Survival 
As a chaperone protein, GRP78 is responsible for translocating newly synthesized 
polypeptides across the ER membrane, facilitating the folding and assembly of proteins, targeting 
misfolded proteins for ER-associated degradation (ERAD), regulating calcium homeostasis and 
serving as an ER stress sensor.13 GRP78 binds misfolded proteins or unassembled complexes and 
initiates ERAD that regulates the UPR.13 GRP78 binds unfolded peptides with the SBD and obtains 
the energy to prevent aggregation by ATP hydrolysis in the NBD.13 In cell homeostasis, GRP78 is 
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bound in an inactive form upon association with activating transcription factor 6 (ATF6), protein 
kinase RNA-like endoplasmic reticulum kinase (PERK) and inositol-requiring enzyme 1 (IRE1) 
that are UPR transmembrane stress sensors.13 Once the cell is exposed to unfolded proteins as they 
accumulate in the ER, the cell senses stress and GRP78 is released from the UPR sensors.1,13 The 
UPR is in its active form and decreases the translation of proteins while enhancing folding 
activity.1,13 In this application, GRP78 is referred to as a master regulator of ER stress since it is 
largely associated with antiapoptotic properties and mediates activation of the UPR signaling 
pathway.13 GRP78 interacts with UPR-induced signaling and apoptotic pathways via activation of 
ATF6, IRE1, PERK that are responsible with increasing translation of ER chaperones, protein 
degradation and translation attenuation.1,12–16 The apoptotic pathway is also achieved by GRP78 
inhibition resulting in the upregulation of caspase proteins.13 
Under ER stress, GRP78 is released from ER transmembrane signal transducers including 
PKR-like ER kinase (PERK) inositol-requiring enzyme 1 (IRE1) and activating transcription 
factor 6 (ATF6).13 This dissociation enables activation of the UPR signaling pathways.13 PERK 
dimerizes to promote autophosphorylation and activation that in turn phosphorylates the 
eukaryotic translation-initiation factor 2  (eIF2) to attenuate the rate of translation initiation and 
prevent further protein synthesis.13 Phosphorylated eIF2 can also selectively increase translation 
of transcripts containing inhibitory upstream open reading frames (uORFs) in the 5’ untranslated 
region such as activating transcription factor 4 (ATF4).13 Once ATF4 is released from GRP78, it 
translocates from the ER to the Golgi and is cleaved.13 This cleavage event allows ATF6 to migrate 
to the nucleus where it serves as an active transcription factor for ER chaperone protein expression, 
including GRP78 and GRP94 as well as folding enzymes such as PDI.13 Release of IRE1 activates 
the endoribonuclease activity that splices a 26-base intron from the mRNA encoding the X-box 
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binding protein 1 (XBP-1).13 XBP-1 is a transcription factor for DnaJ, p58, ERdj4, EDEM, and 
PD1 that are involved in protein folding and ERAD.13 
UPR activation and signaling ultimately results in cell death through apoptosis during 
unrestricted ER stress conditions.13 Stress induction within the ER causes BH3, a proapoptotic 
protein BAX/BAX in the ER membrane to undergo a conformational change resulting in Ca2+ 
efflux to the cytosol.13,17 This efflux activates m-calpain that cleaves and activates procaspase 12 
and the caspase cascade.13 Activation of IRE1 enables binding to c-Jun-N-terminal inhibitory 
kinase (JIK) that recruits TRAF2 leading to the activation of apoptosis signal-regulating kinase 1 
and c-Jun amino terminal kinase (ASK1/JNK).13 This releases procaspase 12 from the ER. 
Likewise, proapoptotic p53-upregulated modulator of apoptosis (PUMA) and NOXA are activated 
that result in activation of BAX and BAK resulting in apoptosis.13 
In addition to apoptosis, ER stress also results in induction of autophagy, or the catabolic 
process for degradation and recycling of cytosolic or aggregated proteins and defective 
organelles.13 This process promotes cell survival by utilizing intracellular resources for waste 
management and turnover of cellular components.13 GRP78 is essential for UPR activation and 
promotes cytoprotective autophagy by maintaining ER integrity.18 Thus, GRP78 induction confers 
cell survival under ER stress or nutrient starvation conditions by promoting autophagosome 
formation which inhibits proteasome activation and cell death signaling.   
 
3.1.3 The Role of GRP78 in Cancer 
GRP78 has a well-defined role and has been established as a clinically relevant biological 
marker in human cancers.13,16,19–21 Among the many hallmarks of GRP78 tumorigenic activity is 
its ability to act as an antiapoptotic and pro-survival factor in pathological cells undergoing ER 
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stress.13 Therefore, elevated GRP78 levels have been detected in cancer cell lines, solid and 
hematological tumors as well as human cancer biopsies associated with malignancy and 
metastasis.13 Elevation, or upregulation, of GRP78 suggests a distinct involvement in enhancing 
cell survival.13 Mechanistically, GRP78 interacts with apoptotic intermediates to block caspase 
activation and inhibit apoptosis leading to cell survival, a common hallmark of cancer biology.5,13 
Likewise, GRP78 is responsible for maintaining ER integrity and stress-induced autophagy in 
transformed neoplastic malignancies.13,18 Thus, expression of GRP78 is higher in primary tumors 
such as breast cancer, hepatocellular carcinoma, lung and prostate cancers, among many other 
tumor types compared with benign tissues.13 
 In cancer, GRP78 has also been found localized at the cell surface where it functions in 
signaling tumor initiation, proliferation, spread and adhesion to surrounding tissues as well as a 
protective marker for treatment resistance.22,6 For example, cell surface GRP78 has been 
associated with initiation, progression and migration of breast cancers correlated with high 
phosphorylation levels of the signal transducer and activator of transcription 3 (STAT3).23 Surface 
GRP78 (sGRP78) has also been identified as a tumor biomarker on gliomas due to its profound 
effects on tumor proliferation.24 Antibody blocking of sGRP78 attenuated tumor growth and 
resulted in concomitant induction of cancer cell death. Thus, targeting and inhibiting GRP78 
function in cancer may prove to be an effective therapeutic strategy in tumors that upregulate 
and/or express GRP78 at the cell surface.  
Cancer treatment has been marked by the challenge of tumor resistance.13 However, 
GRP78 levels may be a prognostic indicator or diagnostic marker for chemoresponsiveness.13 
Clinical analysis of GRP78 expression levels has been explored, revealing that in a patient with 
breast cancer, GRP78 expression levels were used to indicate responsiveness to doxorubicin 
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(Adriamycin)-based chemotherapy.13 Again, in a patient with prostate cancer, GRP78 may be 
utilized to infer resistance to chemotherapy or castration resistance.13  
There are three molecular mechanisms by which tumor growth is dependent on GRP78.13 
Tumor cell proliferation is inhibited by Grp78 heterozygosity which may be due to GRP78 
function as an ER chaperone in growth-factor secretion and/or growth-factor receptor 
maturation.13 This results in GRP78 expression on the cell surface of tumor cells that then enhances 
AKT signaling resulting in cell proliferation and survival.13 GRP78 protects tumor cells from 
apoptosis where tumor cells from heterozygous mice exhibit enhanced TUNEL staining and 
upregulation of CHOP as markers of cell death responses.13 Tumor vascularization is reduced in 
Grp78 heterozygosity but not in normal organs or tissues.13 This suggests that angiogenesis, which 
is required for growth and survival, is dependent on GRP78.13 
In addition to association with cancer malignancy and metastasis, GRP78 is also 
responsible for drug resistance in a variety of cancers including breast, prostate , lung and brain 
cancers.13,25 Resistance is largely accomplished by GRP78 induction in the tumor 
microenvironment resulting in  UPR protective parameters.13 Here, ER stress will result in GRP78 
induction that ultimately leads to resistance.13 Alternatively, inhibition or silencing of GRP78 
expression has resulted in a reversal of treatment resistance and sensitization of resilient tumors to 
treatment efficacy. In primary cultures of human brain endothelial cells, derived from blood 
vessels of malignant glioma tissues (TuBEC), resistance to chemotherapeutic agents such as CPT-
11, etoposide and temozolomide (TMZ) was overcome by GRP78 knockdown using siRNA or 
chemical inhibition with the green tea component (-)-epigallocatechin gallate (EGCG).26 Thus, 
targeting GRP78 has been proven to sensitize the tumor vasculature to chemotherapeutic drugs, 
enhancing their efficacy in combination therapy for glioma treatment.  
 76 
3.1.4 GRP78 as a Clinically Relevant Biological Marker for Cancer Detection and Treatment 
The discovery of GRP78 localization to the cell surface has incited its potential role in 
cancer detection and therapy.13 Proof-of-principle studies indicates cell-surface GRP78 in tumors 
may mediate cancer-specific therapy in prostate and breast cancer cells or xenograft models to 
target tumors with circulating ligands.13,27 Previous studies have reported that synthetic GRP78 
ligands such as the Taxol-conjugated cell-penetrating peptidic GRP78 ligand, was effective in 
targeting and killing cancer cells by recognition of sGRP78.13 Likewise, rK5, an antiangiogenic 
and proapoptotic ligand, was found to interact with surface GRP78 on stimulated endothelial cells 
as well as hypoxic and cytotoxic stressed tumor cells.13 
In the clinic, elevated GRP78 has been observed with higher pathological grade, recurrence 
and poor patient survival in cancers such as breast, liver, prostate, colon and gastric.19 Prostate 
cancer patients were observed to have autoantibodies against GRP78 at high levels that were 
associated with aggressive tumor behavior.19 It has been found that tumors positive for GRP78 are 
resistant to topoisomerase inhibitors.19 Two-thirds of breast cancer patients experienced high 
levels of GRP78 in biopsies before and after treatment with Adriamycin-based regimens that 
indicated a higher risk of recurrence.19 
Cancer cell survival is dependent on GRP78 that is therefore an ideal target for anti-cancer 
agents.19 Genistein, an active ingredient in soy, (-)-epigallocatechin gallate (EGCG), a green tea 
component and salicylic acid from plants are all naturally occurring compounds that inhibit GRP78 
expression.19 Versipelostatin is a macrocyclic compound that inhibits transcriptional activation of 
Grp78 via glucose starvation and selectively kills glucose-deprived cancer cells.19 
In addition, GRP78 silencing using short hairpin (shRNA) or small interfering (siRNA) 
RNA has resulted in anti-cancer activity in cells and in vivo. siRNA targeting GRP78 was found 
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to inhibit the growth of renal carcinoma cells.28 This effect was found to be closely correlated with 
the enhancement of UPR downstream signaling molecules (CHOP, EDEM1, and ERdj4 mRNA) 
likely due to a compensatory effect associated with GRP78 knockdown. In combination with ER 
stress inducers (tunicamycin, MG132, and 2-deoxyglucose) cell viability was significantly reduced 
suggesting that GRP78 knockdown in combination with ER stress inducers might be an effective 
strategy for cancer therapy targeting UPR-induced apoptosis. 
sGRP78 has also been classified as a diagnostic marker for the selective detection of a wide 
range of GRP78+ tumors.29 For example, the anti-GRP78 monoclonal antibody (MAb159), was 
ligated with a 64Cu-DOTA chelator labeled radiotracer for positron emission tomography (PET) 
imaging of GRP78 expression in BxPC-3 pancreatic cancer mice xenografts.30 This positive 
correlation confirmed GRP78 as a valid target for pancreatic cancer imaging. This diagnostic 
approach would also be applicable to identify other, related sGRP78+ tumors at the earliest stages 
of disease progression.  
Together with these findings, recent discoveries in sGRP78 present a novel opportunity to 
utilize sGRP78 as a cancer-targeting marker.19 Here, proof of principle exists as synthetic chimeric 
peptides with GRP78 binding motifs fused to proapoptotic sequences may be systemically 
administered without affecting normal cells.19 As such, GRP78 targeting peptides linked to Taxol 
to induce apoptosis in targeted cancer cells.19 
 
3.1.5 GRP78-Targeting Peptides for Cancer Detection and Treatment   
 The GRP78-recognition, tumor-targeting peptide, Pep42, is a cyclic 13-mer oligopeptide 
of sequence CTVALPGGYVRVC with a terminal disulfide bond.31 Pep42 specifically binds to 
GRP78 and is internalized in a number of cancer cell lines.31 Cell uptake studies revealed that 
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Pep42 is internalized via receptor mediated endocytosis and then trafficked to the lysosome that 
contains proteases such as cathepsin B.31 Cathepsin B is a cysteine protease and ubiquitously 
expressed in the lysosome.31 Pep42-drug conjugates including the ligation of Taxol, porphyrin 
analogs as photosensitizers and cytotoxic peptide sequences such as D-(KLAKLAK)2 have also 
been designed and developed to contain cathepsin B-cleavable linkers such that these drug 
conjugates are stable throughout circulation and may release their drug at targeted tumor upon cell 
uptake.31,31–33 Moreover, poly(arginine) derived Pep42 has also been developed in order to 
improve its cell uptake efficiency rendering the Pep42-poly(arginine) sequences potentially useful 
for gene delivery applications.34 
 The GRP78-binding peptide sequence WIFPWIQL also displays high efficacy in tumor-
targeted drug delivery.35 This peptide was originally selected by phage display and subsequently 
coupled to a proapoptotic moiety  to create the bone metastasis targeting peptide 78 (BMTP78).35 
This peptide was found to induce apoptosis by receptor-mediated internalization in cancer cells.35 
Furthermore, peptide-based drug conjugates containing this sequence and N-(2-hydroxylpropyl) 
methacrylamide (NPMA) polymers were applied for the delivery of the anticancer agent 
geldanamycin to GRP78+ DU145 prostate cancer cells.36 In this application, the conjugate bound 
to sGRP78 with affinities comparable to the native peptide and demonstrated increased 
cytotoxicity in prostate cancer cells when compared to the nonspecific controls. 
 Additional sGRP78-targeting peptides have been selected by phage display and proven to 
bind to a wide range of GRP78+ tumors for detection and treatment.27,37,38 Thus, GRP78-targeting 
peptides encompass an important class of tumor-homing agents with selective theranostic (therapy 
+ diagnostic) utility.  
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3.2 Chemical Biology of the Activating Natural Killer Cell Receptor NKp30 
NK cell biology, in addition to the immunostimulatory activities of B7H6 and related 
peptide ligands has been extensively discussed in the introduction chapter of this thesis. This 
section will briefly describe some of the more relevant applications related to biological and 
immunological studies involving the cancer-targeting immunostimulatory peptides described in 
this chapter.   
NK cells target tumor and virally infected cells in the absence of MHC restriction with a 
combination of signals from activation and inhibitory receptors.39 The natural cytotoxic receptors 
(NCRs) are a group of activating receptors that include NKp46 (NCR1 and CD335), NKp44 
(NCR2 and CD336) and NKp30 (NCR3 and CD337).39 NKp30, also known as natural cytotoxic 
receptor 3 (NCR3), is a 30 kDa protein expressed on all mature resting and activated NK cells.39,40 
NCR3 is encoded in the class III region of the major histocompatibility complex (MHC) in 
humans.39,40 There are six alternatively spliced transcripts from the NKp30 gene, including 
NKp30a to NKp30f.40 
There are three types of NKp30 isoforms including NKp30A, NKp30B and NKp30C.19,39,40 
The former two are activating whereas the latter is immunosuppressive.19,39,40 Therapeutic 
interventions with NK cells should aim to produce an NK cell-dependent anti-tumor immune 
response to avoid immune evasion including a shift from NKp30C expression towards NKp30A/B 
isoforms, an increase in B7H6 surface expression on target cells and a depletion of immune 
compromising soluble ligands such as sB7H6.19,39,40 
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3.2.1 NKp30 Structural Biology 
NKp30 is a type 1 transmembrane glycoprotein with a single Ig-like extracellular domain 
that is connected to a transmembrane and cytoplasmic domain by a short stalk region of six 
residues (Figure 3.3).39,40 The Ig-like extracellular domain has a two-layer -sandwich with chain 
topology found in IgC domains.39,40 The front sheet is composed of -strand GFC where the back 
sheet is composed of ABED and both are linked by a canonical intersheet disulfide bond (Cys39-
Cys107).39,40 The structure also contains two -helices (1 and 2) before the -strands D and E, 
whereby 1 is unique to NKp30.39,40 
 
 
Figure 3.3. Structure of the NKp30 receptor.41 
 
 The closest homologue of NKp30, identified by a Dali structure homologue search with a 
Z-score 12.8%, is the V-like domain of PD-L1, a T cell inhibitory receptor PD-1 ligand.39,40,42 The 
difference between NKp30 and PD-L1 was explored by superposition and a root mean squared 
(r.m.s.) difference of 1.8 Å was observed for 101 -carbon atoms.39,40,42 This structural similarity 
between NKp30 and PD-1 was lower with a Z-score of 10.8 meaning that NKp30 is more 
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structurally similar to the PD-L1 ligand than to the PD-1 receptor.39,40,42 However, these findings 
are unremarkable considering NKp30 is a member of the CD28 family that includes PD-1 
(CD279), CTLA-4 (CD152), ICOS (CD278) and BTLA (CD272).39,40,42 It was also observed that 
the -strands GFC located in the front sheet domain and the ABE strands located in the back sheet 
region of NKp30 align well with the corresponding strands of PD-1 and CTLA-4 (Figure 
3.4a).39,40,42 However, large differences on one side of the -sandwich were observed and there are 
additional strands (notably C’C’’ or C’) that are absent in NKp30 which contains the 1 and 2 
connected by a short D strand.39,40,42 Importantly, the 2 domain binds the NKp30 activating ligand 
B7H6 (Figure 3.4b).39,40,42 In the B7H6:NKp30 ligand:receptor bound structure, NKp30 uses front 
and back -sheet domains to engage binding to the Ig-like V region of B7H6 by hydrophobic 
interactions.39,40,42 
 
 
Figure 3.4. Structures of a) NKp30 overlaid with PD-1 and b) B7H6 bound to NKp3041,43 
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3.2.2 B7H6 as an NKp30 Activating Ligand  
The B7 glycoproteins are a family of ligands for the T cell costimulatory receptor CD28 
and the coinhibitory receptor CTLA-4.42,44 Within the B7 family exists B7H6, a ligand comprised 
of two Ig domains.42,45 This ligand has an extracellular portion composed of a distal V-like domain 
and a membrane proximal C-like domain.42,46,47 In solution, B7H6 behaves as a monomer.42,46,47 
When compared to PD-L1, B7H6 shares significant structural similarity with a Z-score of 16.9 
(20% sequence identity) and r.m.s. difference of 2.8 angstroms (191 -carbon atoms).42,46,47 Most 
importantly, B7H6 is expressed on human tumor cell lines including T and B cell lymphomas, 
melanomas as well as many solid and hematological tumors but typically not on normal human 
tissues.42 The B7H6 interaction with NKp30 induces an NKp30-specific NK cell 
immunostimulatory response mediated by the secretion of cytotoxic cytokines such as TNFα and 
IFNγ.6,42 
 NKp30 has binding affinity for B7H6 and this complex forms a structure with a 1:1 
receptor-ligand stoichiometry.42,46–48 The binding interface is formed by the NKp30 front and back 
-sheets and the V-like domain of the B7H6 front -sheet.42,46,47 Here, NKp30 residues from 
strands CF and loops BC and FG on the front sheet as well as the helix 2 on the back sheet 
juxtapose B7H6 residues from strands GFCC’ and loops BC, C’C’’ as well as FG on the front 
sheet.42,46,47 The NKp30-B7H6 interface is formed as 12 NKp30 residues contact 11 B7H6 residues 
primarily through hydrophobic interactions. NKp30 has three potential N-linked glycosylation 
sites.42,46,47 These sites are located on the outside of the interface and therefore theoretically do not 
interfere with binding.42,46,47 This interface has high shape complementarity according to 
calculated shape correlation statistic of 0.77 that is at the upper end of the range for protein-protein 
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complexes.42,46,47 The shape correlation statistic is Sc=1.0 for interfaces with geometrically perfect 
fits.42,46,47 
NKp30 receptor binding with activating ligands such as B7H6 allows for phosphorylation 
and activation of the immunoreceptor tyrosine-based activation motifs (ITAMs) in CD3, FcRI 
and DAP12.40,46 This enables recruitment and activation of tyrosine kinases ZAP70 and Syk that 
ultimately result in NK activation and release of pro-inflammatory cytokines.40,46 B7H6 also plays 
a critical role in activating NKp30-dependent immunosurveillance of B7-H6+ tumors. 
Downregulation of B7H6 on tumor cells by histone deacetylase inhibitors resulted in reduced 
NKp30-dependent immunosurveillance of NK cells.44 Thus, B7H6 expression in tumor cells 
serves as an important marker for NK-dependent immunity. 
 In a clinical application, a fusion protein consisting of the ectodomain of B7H6 and the 
CD20 single-chain antibody fragment variable 7D8 was developed for NK dependent 
immunotherapy of lymphoma.49 The B7H6:7D8 was able to simultaneously bind to the CD20+ 
lymphoma cells and the NKp30 receptor which activated human NK cells and triggered 
degranulation. In this manner the bifunctional B7H6:7D8 fusion protein induced NK-dependent 
immunocytotoxicity of lymphomas as well as tumors derived from chronic lymphocytic leukemia 
or lymphoma patients. Thus, B7H6 is also an important engager of NK cells’ cancer 
immunotherapy response in clinical applications. 
 
3.2.3. B7H6-Derived Peptidic Ligands for Activating NKp30 and Natural Killer Cells 
Effector Functions 
In a previous study from our research group, as detailed in the introduction section of this 
thesis, B7H6-derived peptidic ligands were designed, selected, and synthesized for activating 
 84 
NKp30 and NK cell effector functions.13 The rationale for the synthetic peptides was based on the 
co-crystal structure analysis of the B7H6-NKp30 binding complex.9 Peptide sequences were 
selected from the binding site residues of B7H6 with the NKp30 receptor active site.50,51 Structural 
analyses indicated that residues within the FG loop of B7H6 binding site, VTPLK, were imperative 
in B7H6 binding and activation of the NKp30 receptor.50,51 The selected peptide (TVPLN) was 
derived from the VTPLK sequence and was hypothesized to improve NKp30 binding by 
stabilizing the bio-active turn conformation found at this site.  
Binding of the synthetic peptides to NK92-MI cells was established in a concentration-
dependent manner (0.1-10 µM) with FITC-labeled synthetic peptides using flow cytometry.50,51 
Binding specificity was determined by competitive binding experiments with the activating ligands 
(Alexa Fluor 488-labeled B7H6 or the FITC-labeled synthetic peptides) in competition with the 
APC-labeled anti-NKp30 monoclonal antibody.50,51 These binding experiments proved the 
selected B7-H6 derived peptides bound to NK cells with some NKp30 dependence.  
 NKp30 activation was analyzed by evaluating the immunostimulatory activities of B7H6 
and the synthetic peptides onto the human NK92-MI cells.50,51 Here, cytokine content was 
analyzed by ELISA and confirmed the secretion of TNFα, with TVPLN outperforming all of the 
other peptides. No significant IFNγ production was observed from the peptide treated NK cells. 
Thus, the TVPLN sequence was selected as lead peptide ligand capable of binding to NK cells 
with some degree of NKp30 specificity while activating cytokine secretion that may result in 
immunotherapeutic effects. 
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3.3 Chapter Objectives 
In this chapter, the evaluation of our bifunctional trimeric synthetic peptides will be 
described. My contribution to this work was based on the in vitro preclinical studies including 
sample testing, assay optimization and data analysis for  direct binding and specificity to both 
NK92-MI and A549 cells, pro-inflammatory cytokine secretion by Luminex, NK92-MI cells’ pre-
activation and co-culture with the A549 cells analyzed by immunofluorescence, cytotoxicity using 
Annexin V/7AAD staining by flow cytometry and pro-inflammatory cytokine release using 
multiplex Luminex assays. For this work, assistance from Dr. Dante Descalzi, Zheng Yang, and 
Eugenia Dziopa from Dr. Robert Korngold’s group at the Center for Discovery and Innovation at 
Hackensack University Medical Center contributed to the optimization of culture and co-culture 
conditions of NK92-MI and A549 cancer cells in addition to the in vivo testing. We evaluated the 
synthetic peptides for their ability to directly bind to the surface of cancer (A549 or HepG2) cells 
as well as the surface of NK92-MI cells. We also determined the degree (%) of binding selectivity 
to the respective GRP78 and NKp30 receptors on the surface of cancer and NK cells. Furthermore, 
the NK92-MI cells treated with the trimeric peptides were analyzed by Luminex assays to evaluate 
the release of proinflammatory cytokines including TNF, IFN, IL-5, IL-8 and IL-13. Once these 
parameters were established, we conducted a co-culture assay in which NK92-MI cells were 
preincubated with the trimeric synthetic peptides to stimulate, or activate, the release of 
proinflammatory cytokines for 24 hours. The primed NK92-MI cells were then cultured with 
cancer A549 cells for 24 hours to evaluate tumor engagement and elimination with and without 
activating ligands. Post-treatment, the coculture was evaluated for the release of proinflammatory 
cytokines by Luminex assays and cytotoxic events by flow cytometry. NSG mice were 
subcutaneously injected with A549 cells and a tumor developed over the course of two weeks. 
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Once developed, the tumor was injected with the primed NK92-MI cells and tumor growth was 
monitored over time. This chapter will therefore shed insights into the biological and 
immunological activities of the bifunctional synthetic trimeric peptides for NK-dependent 
immunotherapy of selected cancer types. 
 
3.4 Results and Discussion 
3.4.1 Binding Affinity and Selectivity Assays for Trimeric Peptides for GRP78 and NKp30 
Respectively on the Surface of A549 and NK92-MI cells 
The linear GRP78 targeting sequences (Table 2.1., sequences 1-4) as well as a small library 
of bifunctional trimeric peptides incorporating NKp30 binding and NK cell activating TVPLN 
peptides14 and the GRP78-targeting sequences27,32–34,37,38  (Table 2.1., sequences 5-13) were 
designed and developed for evaluating peptide activity. Synthetic trimeric peptides (Table 2.1., 
peptides 5-13) were screened with tumor cells (HepG2 and A549 cells) to determine binding 
capabilities. Among the screened peptides from the library, trimeric peptide 13, designed with the 
NKp30 binding and activating TVPLN14 and the GRP78 targeting WIFPWIQL27 sequences, 
displayed the most promising cell-binding and immunostimulatory responses and bound to a large 
(~89%) population of HepG2 cells according to flow cytometry (Figure 3.7). The binding 
capabilities of the FITC-labeled trimeric peptide 13 was then found to be diminished (~72%) in 
the presence of a GRP78 peptide blocker (Figure 3.7). Comparatively, the anti-GRP78 primary 
antibody bound to a small fraction of live HepG2 cells (~9%) but was found to be completely 
blocked upon pre-treatment of a GRP78-specific peptide blocker (Figure 3.7). Together, this 
suggests that trimeric peptide 13, while exhibiting some GRP78-dependent binding on the HepG2 
cells, contains noticeable non-specific, or unidentified, binding, that is binding to an unidentified 
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location on the cell surface, to this cell line. Moreover, the larger population of peptide-bound 
HepG2 cells (compared to anti-GRP78 primary antibody binding) exhibited noticeable apoptosis 
according to Annexin V/propidium iodide staining thereby diminishing the suitability of this cell 
line for our cancer immunotherapy approach. 
The binding capacity and specificity of the selected tripeptide 13 to the A549 cell line 
(GRP78+/B7H6-) showed comparable cell-line binding to the AF-488 labeled anti-GRP78 primary 
antibody, albeit to a small (4-8%) population of cells (Figure 3.7). Some degree of GRP78 binding 
specificity was detected when the anti-GRP78 primary antibody or tripeptide 13 were respectively 
pre-treated with a GRP78 blocking peptide (Figure 3.7). No peptide toxicity was observed on the 
A549 cells following the treatment conditions. Furthermore, surface B7H6 expression was absent 
in the A549 cells as determined using the FITC-labeled anti-B7H6 primary antibody (Figure 3.8). 
Taken together, these results validate the applicability of the A549 cells as a reliable surface 
GRP78+/B7H6- cell line source for evaluating the need for NK cell binding and activation of the 
lead trimeric peptide ligand. 
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Figure 3.5. GRP78 binding studies on the HepG2 (pink) and A549 (black) cells. Cancer cells 
without treatment served as a negative control. GRP78 expression was measured by addition of 
the AF-488 anti-GRP78 primary antibody. Specificity for GRP78 was measured by addition of 
either the anti-GRP78 Ab followed by the peptide blocker or addition of the trimeric peptide 
followed by the anti-GRP78 Ab. The difference in trimeric peptide 13 binding to A549 and HepG2 
cells was statistically significant (p>0.01). 
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Figure 3.6. B7H6 expression on HepG2 (pink) and A549 (black) cells. Cancer cells without 
treatment served as a negative control while AF-488 anti-B7H6 primary antibody was used to 
measure cell surface B7H6 expression. The difference in B7H6 expression was not statistically 
significant (p>0.05). 
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The binding capabilities of the FITC-labeled synthetic trimeric peptide 13 to the cell 
surface of the human NK cell line, NK92-MI, was also explored and compared to the binding 
capabilities of APC-labeled anti-NKp30 mAb (Figure 3.9). The NK cell binding occupancy 
(~57%) was observed with the FITC-labeled trimeric peptide 13 (Figure 3.9). Competitive binding 
assays were used to determine the degree of specificity with the FITC-labeled trimeric peptide 13 
and the APC-labeled anti-NKp30 primary antibody (Figure 3.9). The NK92-MI cells were initially 
incubated with the FITC-labeled trimeric peptide 13 followed by treatment with the APC-labeled 
anti-NKp30 primary antibody. Flow cytometry revealed complete displacement of the trimeric 
peptide 13, resulting in little bound peptide and replacement with bound anti-NKp30 antibody. No 
observable toxicity was detected from the peptides onto the NK cells. Therefore, the trimeric 
peptide 13 was found to be an NKp30 binding ligand on NK cells. 
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Figure 3.7. Binding and displacement studies on the NK92-MI cells. NK92-MI cells were treated 
with the trimeric peptide 13. Following peptide incubation, the anti-NKp30 Ab was added to 
displace the trimeric peptide from the NK92-MI cells revealing quantities of bound trimeric 
peptide and anti-NKp30 Ab. 
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Immunostimulatory activities of the NK cells were also detected by Luminex assay (Figure 
3.10). The secretion of the pro-inflammatory cytokine IFN and chemokine IL-8 was observed 
when the NK cells were pre-treated with either the lead trimeric peptide 13 or the control B7H6 
ligand. No detectable secretion of TNFα, IL5 and IL13 was detected under these experimental 
conditions. However, these results support the applicability of the lead trimeric peptide 13 as a 
tumor (A549 cells) and NK cell homing peptide with the capabilities of stimulating NK-dependent 
immunity. 
 
 
 
 
 
 
 
 
 
 93 
 
Figure 3.8. Secretion of pro-inflammatory cytokines/chemokines (IFN, TNF, IL-5, IL-8 and 
IL-13) from the effector NK92-MI cells with and without the activating ligands, B7H6 and trimeric 
peptide 13 according to the Luminex assay. No detectable levels of IFN (control, untreated 
conditions), TNFα, IL5 and IL13. Data representative of three independently conducted 
experiments. The difference in IFN and IL8 secretion was not statistically significant (p>0.05). 
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3.4.2 Luminex assay for Evaluating High-Throughput Cytokine Release Activities of the 
Trimeric Peptides (vs controls) in Culture with Cancer Cells 
Co-culture conditions were optimized with the A549 tumor and NK92-MI cells to evaluate 
the immunotherapeutic effects of the lead trimeric peptide 13 compared to controls. The secretion 
of pro-inflammatory cytokines and chemokines was evaluated to elucidate the immunocytotoxic 
nature of the synthetic peptides. A time dependent (1-24 h) Luminex assay was used to detect the 
secretion of pro-inflammatory cytokines/chemokines (IFN, TNF IL-5, IL-8 and IL-13) from the 
effector NK92-MI cells onto the targeted A549 tumor cells with and without the activating ligands, 
B7H6 and trimeric peptide 13 (Figure 3.11). Detectable levels of IFN, TNF and IL-8 were 
observed in all co-culture conditions with a small increase (128-162 pg/mL) in cytokine and 
chemokine secretion with the activating B7H6 and trimeric peptide 13 ligands. However, no 
detectable levels of IL-5 and IL-13 were recorded under these experimental conditions. The 
secretion of IFN is well established with NK cells’ immunostimulatory activity, while TNF and 
IL-8 secretion has also been correlated with NK cell proliferative and cytotoxic activities.52 
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Figure 3.9. Time dependent (1-24 h) secretion of pro-inflammatory cytokines/chemokines (IFN, 
TNF, and IL-8) from the effector NK92-MI cells onto the targeted A549 tumor cells with and 
without the activating ligands, B7H6 and trimeric peptide 13 at (A) 1 hour, (B) 6 hours and (C) 24 
hours according to the Luminex assay. Quantitative values are represented by the mean of 3 trials. 
The difference in IFN and TNF secretion at all time points was not statistically significant 
whereas IL8 secretion was statistically significant (p<0.001). 
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3.4.3 Immunofluorescence Microscopy Demonstrates Tumor Invasion of Activated Natural 
Killer Cells 
A co-culture assay with A549 cells expressing green fluorescent protein (GFP) as reporter 
and NK92-MI cells counterstained with the nuclear Hoechst dye. The NK92-MI cells were initially 
pre-activated with the native NKp30 ligand, B7H6 or the lead trimeric peptide 13 and then 
incubated with the A549 cells (Figure 3.11). Cell-cell interactions between the A549 (GFP+, green) 
and the NK92-MI cells (Hoechst stained, purple) were visualized by fluorescence microscopy with 
and without the activating ligands (B7H6 and trimeric peptide 13). The pre-activated (with either 
B7H6 or the trimeric peptide 13) NK92-MI cells (blue) were observed as clustered around the 
A549 cells (green) (Figure 3.11C and D) and to a more significant extent when compared to the 
untreated co-culture conditions (Figure 3.11B). The association of the effector NK cells to the 
target A549 cancer cells also resulted in noticeable dissipation of GFP signaling from the A549 
cells. This observation was also detected in a time-dependent manner (1-24 h) by flow cytometry 
when the NK92-MI cells were preactivated with either B7H6 or trimeric peptide 13 (Figure 3.12). 
The dissipation of GFP signaling may be likely due to the immunocytotoxicity of the NK92-MI 
cells towards the targeted A549 cells and supports the capacity of the lead trimeric peptide 13 to 
stimulate NK cell activity.   
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Figure 3.10. Visualization of tumor association of the effector NK92-MI cells towards the target 
A549 cells by fluorescence microscopy. A, GFP+ A549 tumor cells (green) B, NK92-MI cells 
stained exclusively with the Hoechst dye (purple) and in co-culture with the A549 cells without 
activating ligands. A549-NK92-MI co-culture with activating ligands, C, B7H6; and D, trimeric 
peptide 13.     
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Figure 3.11. A549 cells expressing endogenous GFP were cultured with NK92MI cells and GFP 
was monitored at 6h and 24h as an indicator of A549 cell death. A) A549 cell number decreases 
from 6h (n=29,732) to 24h (n=13,775) when cocultured with NK92MI cells activated by peptide 
13. The reduction in cell number indicates A549 cell death that is greatest with NK92MI cells 
activated by peptide 13 as compared to those activated by B7H6 or not activated at all. B) A549 
cell number decreases from 6h (n=39,326) to 24h (n=33,514) when cocultured with NK92MI cells 
activated by B7H6. C) A549 cell number decreases from 6h (n=28,293) to 24h (n=19,275) when 
cocultured with NK92MI alone. 
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3.4.4 Cell Death Stages and Extent of Cytotoxicity of the Activated Natural Killer Cells onto 
the Target GRP78+ A549 Cancer Cells Reported By Cell Death Assays 
The immunocytotoxic effects of the ligand activated NK cells towards the targeted A549 
cells was explored by early/late stage apoptosis and necrosis using flow cytometry with Annexin 
V-7-aminoactinomycin D (7-AAD) staining. Following 24 h incubation, early (~75-80%) and late 
(16-21%) stage apoptosis was respectively indicated by Annexin V+ 7AAD- and Annexin V+ 
7AAD+ staining with minimal necrosis (<1%) detected among all co-culture conditions (Figure 
3.13). However, a notably small increase (1-5%) in late stage apoptosis with the activating B7H6 
and trimeric peptide 13 ligands was also observed. A time-dependent study (0-24 h) also confirmed 
comparable NK-dependent immunocytotoxicity of the A549 tumor cells among all co-culture 
conditions which relied on apoptosis rather than necrosis (Figure 3.14). These results suggest that 
peptide 13 may enhance the immunocytotoxicity of the NK92-MI cells towards the targeted A549 
tumor cells. 
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Figure 3.12. Cytotoxicity assay evaluating the extent and type of A549 cell death by A, NK92-MI 
cells (no treatment), NK92-MI cells in addition to B, B7H6 and C, trimeric peptide 13. In all cases, 
early (Annexin V+ 7AAD-) and late (Annexin V+ 7AAD+) stage apoptosis were detected with 
minimal necrosis (Annexin V- 7AAD+). Quadrants indicate cell viability as the following: U--, X-
- and AA-- indicate healthy cells; U-+, X-+ and AA-+ indicate cells undergoing early apoptosis; 
U++, X++ and AA++ indicate cells undergoing late apoptosis and U+-, X+- and AA+- indicate 
necrotic cells. 
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Figure 3.13. Time-dependent toxicity assay measuring Annexin V (early stage apoptosis) in A549 
cells (expressing endogenous GFP) cultured with NK92MI cells (A) alone, (B) after NK92-MI 
pre-activation with B7H6 or (C) after NK92-MI pre-activation with the lead trimeric peptide and 
7AAD (necrosis) in A549 cells cultured with NK92MI cells (D) alone, (E) after NK92-MI pre-
activation with B7H6 or (F) after NK92-MI pre-activation with the lead trimeric peptide 13. 
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3.4.5 In vivo Analysis of Tumor Regression with Time  
The immunocytotoxicity effects detected in cell culture were also studied in vivo. 
Xenogeneic, immunodeficient NSG (NOD.Cg-Prkdc(scid)ll2rg/Szj, NOD SCID mice) mice were 
challenged with A549 tumor cells (5x106) subcutaneously in the right flank. Following 7 days of 
tumor growth, NK92-MI cells (0.5x106) were injected at the localized tumor site alone or with the 
activating trimeric peptide 13 (10 M) and tumor growth was monitored with a digital caliper 
over a 23-day period. Tumor growth reduction was statistically significant and consistently 
reduced with treatment of the NK92-MI cells and the lead trimeric peptide 13 in comparison to 
just the A549 growth alone (Figure 3.15). A small but consistent decrease in A549 tumor growth 
at all time points was also observed with the peptide 13 pre-activated NK92-MI cell group, albeit 
without statistical significance when compared to NK92-MI cell treatment alone. This trend 
suggests that peptide 13 pre-activation of the NK92-MI cells may sustain immunocytotoxicity of 
the targeted A549 tumor cells in vivo.  
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A B  
Figure 3.14.   A549 tumor growth in vivo: A, tumor size measurements; and B. tumor growth rate 
curves over a 23-day period. NSG mice were challenged with A549 tumor cells and monitored 
after receiving no treatment (A549), NK92-MI cells alone (A549 + NK CELLS), or peptide 13 
pre-activated NK92-MI cells (PEPTIDE). ANOVA statistical analysis was performed, and the 
PEPTIDE group was statistically (p<0.05) and consistently lower in tumor size at all time points 
than the A549 control group.  The PEPTIDE group also trended consistently lower in tumor size 
than the A549 + NK group but without statistical significance (p=0.6746). 
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3.5 Conclusions 
A new class of CTIP has been designed and developed for cancer immunotherapy 
applications. A simple, yet versatile solid phase peptide synthesis strategy was implemented for 
the divergent synthesis of Y-shape bifunctional trimeric peptides. A lead bifunctional trimeric 
peptide 13 was selected from a cell binding screen of a small library of peptides and was found to 
display NKp30 binding and NK cell activating as well as GRP78-targeting and tumor cell binding 
capabilities with some degree of specificity. In co-culture, the target A549 tumor cells were visibly 
associated with the NK cells when pre-activated with the lead trimeric peptide 13. Consequently, 
the A549 cells underwent early and late stage apoptosis most likely due to the detectable secretion 
of the pro-inflammatory cytokines and chemokines (IFNγ, TNFα and IL-8) from the activated NK 
cells. Furthermore, peptide 13 activation of NK cells, followed by injection into A549 tumor 
bearing mice revealed a consistent decrease in tumor growth rates compared to the untreated 
control. The identification of a lead trimeric peptide 13 capable of targeting and activating NK 
cells’ immunotoxicity directly towards resilient GRP78+/B7H6- tumors provides a novel entry 
point for using CTIPs for cancer immunotherapy applications.  
 
3.6 Experimental Section 
3.6.1 Cell Lines and Cell Culture 
The human hepatocellular carcinoma cells HepG2 were purchased from (ATCC® HB-8065™) 
and cultured in Eagle’s Minimum Essential Medium (EMEM) media supplemented with 10% (v/v) 
Fetal Bovine Serum (FBS) and 1% (v/v) Penicillin/streptomycin (P/S) under 5% CO2 at 37 oC. 
The human lung epithelial carcinoma cells A549 were purchased from (ATCC® CCL-185™) or 
A549 cells expressing endogenous Green Fluorescent Protein (GFP) (MyBioSource, Catalog No. 
 105 
MBS168483) and cultured in ATCC-formulated F-12K media supplemented with 10% (v/v) Fetal 
Bovine Serum (FBS) and 1% (v/v) Penicillin/streptomycin (P/S) under 5% CO2 at 37 oC. For 
passaging, cells were detached with 0.25% trypsin and re-suspended with complete culture 
medium. The recombinant human B7H6 protein (100 g/mL, R&D Systems, Catalog No. 7144-
B7-050) was labelled with AlexaFluor488 using the AlexaFluor 488 MicroScale Protein Labeling 
Kit (Thermofisher, Catalog No. A30006). For experimentation, cells were detached with TrypLE™ 
Express Enzyme (ThermoFisher, Catalog No. 12605010). The human natural killer NK92MI cells 
were purchased from (ATCC® CRL-2408™) and cultured in Myelocult media supplemented with 
10% (v/v) Fetal Bovine Serum (FBS) and 1% (v/v) Penicillin/streptomycin (P/S) under 5% CO2 
at 37 oC.For co-culture experiments, NK92MI cells (100,000 cells/well) with and without B7H6 
or the synthetic peptide activation was initially cultured in a 96-well plate for 24 hours. The GFP-
expressing A549 cancer cells (25,000 cells/well) were then added to the NK92MI cells (100,000 
cells/well) at a 1:4 ratio and incubated for 24 hours at 5% CO2 at 37 oC. All cells were then 
collected and evaluated for cytotoxicity by Annexin V/7-AAD staining using flow cytometry or 
cytokine secretion by Luminex.  
 
3.6.2 Flow Cytometry  
For detection of cell surface expression levels of GRP78, B7H6 or NKp30, the target HepG2 
and A549 cancer cells or the effector NK92-MI cells, respectively, were washed with FACS buffer 
(1X PBS, 1% BSA, 100,000 cells/mL), and then treated with either the APC-labeled human 
NKp30 monoclonal antibody (5 L per 100,000 cells, BioLegend, Catalog No. 325210) or the 
AF488 labelled anti-GRP78 polyclonal antibody (0.5 mg/mL, SantaCruz Biotechnology, Catalog 
No. sc1050 or Invitrogen, Catalog No. 53-9768-82), or the AlexFluor-488 AF-488 labelled anti-
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B7H6 primary antibody (0.2mg/ml) (R&D Systems, Catalog No. FAB71442G) and incubated at 
room temperature for 20 minutes in the dark. Cells were then washed and analyzed on a Cytomics 
FC500 flow cytometer using the 488 nm and 633 nm lasers, respectively, to detect the FITC/AF-
488 or APC fluorochromes. 
To determine direct binding of the synthetic trimeric peptide 13, HepG2, A549 or NK92-MI 
cells were washed with FACS buffer and suspended with the trimeric peptide 13 (10 M in 1X 
PBS) for 15 min (R.T., dark), washed and analyzed by flow cytometry.  
For competitive blocking studies, HepG2 or A549 cells were initially treated with the GRP78 
peptide blocker (0.5 mg/mL in 1X PBS buffer, SantaCruz Biotechnology, Catalog No. sc1050) for 
15 min. HepG2 or A549 cells were washed with FACS buffer, centrifuged and treated with either 
the FITC-labeled trimeric peptide 13, (10 M in 1X PBS) or the FITC labelled anti-GRP78 
polyclonal antibody (0.5 mg/mL, 1X PBS) for an additional 15 min (RT, dark). Cells were finally 
washed with FACS buffer and analyzed by flow cytometry. 
For competitive displacement studies, NK92-MI cells were initially treated with the FITC-
labeled trimeric peptide 13, (10 M in 1X PBS) for 15 min (RT, dark). NK cells were then washed 
with FACS buffer, centrifuged and treated with the APC-labeled human NKp30 mAb (5 L in 1X 
PBS) for another 15 minutes (R.T., dark). Cells were then washed with FACS buffer and analyzed 
by flow cytometry. 
Flow cytometry was also used to determine cell viability monitoring early and late-stage 
apoptosis, as well as necrosis using Annexin V/7-AAD stain kit (Biolegend, Catalog No. 640934). 
The NK92-MI cells (125,000 cells/well) were incubated with and without the activating ligands, 
synthetic trimeric peptide 13 (10 M in 1X PBS buffer) or B7H6 (1 mM, 1X PBS buffer) for 20 
min in a 96 well plate at 37°C in 5% CO2 humidified air. NK cells were then collected and washed 
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with FACS buffer, centrifuged, and suspended with the A549-GFP cells (50,000 cells/well), 
expressing endogenous GFP, and incubated for 24 hours at 5% CO2 at 37 oC. A549 cells were then 
collected and washed with FACS buffer, centrifuged, and suspended in Annexin V/7-AAD stain 
kit (5 L/tube). Following incubation (20 min) at room temperature in the dark, the A549 cells 
were analyzed for early, late apoptotic events and necrosis by flow cytometry following the vendor 
instructions.  
 
3.6.3 Multiplex Luminex Assay  
NK92MI cells were seeded on 96-well plates at a density of 105 cells/well. After 24 hours, 
cells were treated with and without, AF488-labelled B7H6 (100 g/mL, R&D Systems, Catalog 
No. 7144-B7) and the synthetic trimeric peptide 13 (10 M in 1X PBS) for 24 hours. Cytokine 
content in the culture media was analyzed using multiplex Luminex bead technology according to 
the manufacturer’s instructions on a Luminex 200 (Luminex, Austin, TX). Calibration of the 
Luminex 200 was performed prior to each run (Luminex Corp, Catalog No. LX200-CAL-K25) to 
exclude the possibility of instrument-related fluorescence intensity changes over time. Standard 
curves of known concentrations of recombinant human cytokines were used to convert median 
fluorescence intensity (MFI) to cytokine concentration in pg/mL. 
For the co-culture assay, NK92MI cells were seeded on 96-well plates at a density of 125,000 
cells/well. After 24 hours, cells were primed with and without the activating ligands, B7H6 (1 M, 
RND Systems, Catalog No. 7144-B7) and the synthetic trimeric peptide 13 (10 M in 1X PBS) 
for 24 hours to initiate the release of immunostimulatory cytokines and/or chemokines. The A549-
GFP cells (50,000 cells/well), expressing endogenous GFP, were then added to the NK cells with 
and without the activating ligands and incubated for 24 hours at 5% CO2 at 37 oC. Any decrease 
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in GFP signal was measured by flow cytometry in a time-dependent manner (0-24 hours). Cell 
lysates from each time point were used for the analysis of cytokine and/or chemokine content in 
the culture media by multiplex Luminex assay. 
 
3.6.4 Immunofluorescence Microscopy  
Immunofluorescence imaging of endogenous GFP-expressing A549 cells (50,000 cells/well) 
cultured with NK92-MI cells (125,000 cells/well) with or without pre-treatment from the 
activating ligands, B7H6 (1 M, RND Systems, Catalog No. 7144-B7) or trimeric peptide 13 (10 
M in 1X PBS) were captured on a Nikon Eclipse Ti2 fluorescent microscope (Nikon) and 
analyzed using NIS-Elements AR (Nikon). Cells were counter-stained with Hoescht 33342 (20 
mM) (ThermoFisher, Catalog No. 62249). 
 
3.6.5 In-vivo Assay 
NSG mice (10 males and 7 females) were subcutaneously injected with A549 cells (ATCC® 
CCL-185™) mixed with Matrigel (Corning, Catalog No. 356255) (500,000 cells/ 50 L) and the 
tumors were allowed to grow for 7 days. Two treatment groups were established: NSG mice with 
developing A549 tumor to be injected with NK92MI cells only and NSG mice with developing 
A549 tumor to be injected with trimeric peptide 13 pre-treated NK92MI cells. NSG mice with 
developing A549 tumor served as a negative (no treatment) control. Following tumor growth, 
NK92MI cells (500,000 cells, 1X PBS) with and without pre-incubation with  trimeric peptide 13 
(10 M, 1X PBS) for 30 min to induce an immunostimulatory response were directly injected into 
the A549 tumor site located on the left flank of the NSG mice. Tumor growth was monitored over 
23 days and recorded with a digital caliper. Following monitoring of tumor growth, mice were 
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euthanized by CO2 in a gradual fill method to reduce discomfort as recommended in the current 
AVMA Guidelines (2020) and tumor tissue isolated and cryogenically preserved using the optimal 
cutting temperature technique for future evaluation.  
 
3.6.6 Statistical Analysis  
Statistical analysis was performed on GraphPad Prism 8. One-way ANOVA with multiple 
comparisons was used to determine statistical significance among treatment groups in accordance 
with the use of one factor, tumor volume or cytokine release, being analyzed.  
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Chapter 4: Contributions to Knowledge and Future Work 
 
4.1 Conclusions and Contributions to Knowledge Accomplished in this Thesis 
4.1.1 The Discovery of Trimeric B7H6-Derived and GRP78-Targeting Immunostimulatory 
Peptides of Lymphocytic NK92-MI Cells 
This thesis reports the design, synthesis and characterization of bifunctional trimeric 
peptides with B7H6-derived NKp30 binding motifs that can also serve to activate NK cells’ 
immunocytotoxicity and GRP78-binding motifs that can target tumors that express surface 
GRP78. The peptides are designed to mimic the targeting and effector functions of bispecific 
antibodies while expanding the repertoire of bio-active synthetic peptide candidates in cancer 
immunotherapy applications. The peptides directly bind and activate effector NK92-MI cells while 
also recognizing and binding to target A549 tumor cells to facilitate NK cell-dependent 
immunocytotoxicity of the targeted tumors. This cancer immunotherapy approach is not only 
anticipated to reveal the targeting and effector functions associated with synthetic antibody mimics 
but also provides the potential for generating synthetic peptide vaccines against resilient tumors. 
This is because the tumor associated B7H6 antigen is often downregulated or shed from the surface 
of tumors resulting in evasion of NK-dependent immunity and tumor resistance. The bifunctional 
peptides are designed to overcome this limitation and restore NK cell immunity, even within the 
more resilient B7H6 deficient tumors. This thesis provides a proof-of-concept discovery on the 
potential to develop bifunctional peptide ligands that can restore and/or activate NK cell activity 
against these tumor types.    
In order to test our hypothesis, we initially optimized a synthetic approach that facilitated 
the construction of the bifunctional trimeric peptides on solid phase. This de novo solid phase 
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peptide synthesis approach facilitated a divergent synthesis of the branched trimeric peptides from 
an orthogonally protected lysine that served as branchpoint synthon. Its implementation facilitated 
the selective synthesis of the NKp30 binding and activating peptides (TVPLN) synthesized as 
linear dimers as well as the GRP78 targeting peptide (WIFPWIQL) emanating from the 
branchpoint lysine position. Moreover, this synthetic methodology was amenable to the 
incorporation of fluorescent reporter probes (e.g. FITC) for tracking peptide biology. Following 
synthesis, peptides were isolated from the solid support, purified and characterized by a 
combination of liquid chromatography mass spectrometry (LCMS) as well as UV-Vis 
spectroscopy.  
  Direct binding of the trimeric peptides to both surface NKp30 and GRP78 cell lines, 
NK92-MI and A549 cells respectively, was determined using flow cytometry. A lead synthetic 
bifunctional trimeric peptide 13, displayed binding occupancy to the NK and A549 cells with some 
degree of receptor binding specificity according to blocking and/or competition studies. Moreover, 
peptide 13 also triggered NK-dependent immunostimulatory activity, with specific observed 
secretion of IFN and IL-8. Thus, the synthetic bifunctional trimeric peptide 13 was selected as 
lead peptide candidate to evaluate NK activity in co-culture with the GRP78+/B7H6- A549 cell 
line. When the trimeric peptide pre-activated NK92-MI cells were cultured with A549 cells, the 
pro-inflammatory cytokines TNF, IFN and IL-8 were observed. The release of pro-
inflammatory cytokines in co-culture also resulted in observed cytotoxic responses towards the 
targeted tumor cells that were found to undergo apoptosis during the treatment conditions. The 
bifunctional targeting and effector functions of the lead trimeric peptide 13 were also established 
by fluorescence microscopy which revealed visible association of the NK cells to the A549 tumor 
cells which also resulted in diminished green fluorescent protein (GFP) signaling from the GFP-
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labeled A549 cells. The latter effect was observed in a time dependent manner, suggesting 
compromised cell integrity and a transition to cell death of the targeted tumor cells. Cell viability 
staining (Annexin V/7-AAD) monitoring the type and extent of cell death confirmed NK-
dependent immunocytotoxicity of the targeted A549 tumor cells when pre-activated with the lead 
trimeric peptide 13.  
We then tested peptide activity in vivo, within A549 tumor-bearing NSG mice. In this 
assay, trimeric peptide 13 was used to pre-activate NK92-MI cells followed by direct injection at 
the localized tumor site. Tumor reduction as a function of time was monitored for nearly a month.  
Peptide treatment did reduce the rate of tumor growth compared to the control conditions, albeit 
with statistical significance to the no treatment control and without significance when compared 
to the treatment conditions consisting of NK cells without peptide pre-activation. Thus, peptide 
treatment was shown to maintain NK anti-cancer activity in cell-based and in vivo assays 
validating the utility of our approach for cancer immunotherapy applications.     
 
4.2 Future Work 
4.2.1 Continuation with GRP78-targeting and NKp30-targeting Immunostimulatory 
Peptides 
The NKp30-selected binding sequence, TVPLN, proved effective in both specifically 
recognizing and binding to NKp30 as well as initiating an immunostimulatory response with the 
release of the pro-inflammatory cytokines, TNF, IFN and IL-8. However, we selected trimeric 
peptide 13 with the GRP78-binding sequence WIFPWIQL. Here, this sequence exhibited some 
degree of non-specific, or unidentified, binding to both A549 cells as well as HepG2 cells, with a 
higher degree of non-specific, or unidentified, binding to the HepG2 cells. For this reason, we 
 117 
chose to focus our model cancer cell line on the A549 cells. Future work, may be geared to improve 
cell line binding specificity using a wider range of surface GRP78 expressing tumors.1 The 
inclusion of cell lines which lack surface GRP78 may also serve as suitable controls to evaluate 
the specific targeting capabilities of the selected lead bifunctional peptides.2 
Wang and Yu3 previously studied the WIFPWIQL and RLLDTNRPLLPY sequences for 
GRP78 binding activity using the Biacore protocol associated with surface plasmon resonance 
(SPR) to evaluate the timely dissociation of peptides from the oriented immobilization of protein 
in this peptide-binding assay.3 Here, they observed the binding dissociation of the WIFPWIQL 
sequence occurred at a faster rate than the RLLDTNRPLLPY.3 These results may be used to shift 
the focus of GRP78-targeting peptides to utilize the RLLDTNRPLLPY sequence which may 
exhibit greater binding affinity and specificity compared to the WIFPWIQL sequence.3 
 
4.2.2 Further Evaluation of the Trimeric Peptide 
 For the purpose of this study, we directly injected NK92-MI cells pre-activated with the 
trimeric peptide into A549 tumors on tumor-bearing NSG mice and then monitored tumor growth 
for a total of 23 days. The observed regression in tumor size and reduction in tumor growth rate 
was promising, however, not to a statistically significant extent relative to the non-peptide NK cell 
treatment control. To confirm the peptide effects in vivo, determination of NK dependent pro-
inflammatory responses and tumor toxicity should be further evaluated with and without peptide 
treatment conditions. In order to improve peptide activity in vivo, i) the incorporation of modified 
or un-natural amino acid residues may serve to enhance peptide bioavailability and stability,4 ii) 
the incorporation of additional immunogenic sequences and/or adjuvants may help boost NK 
responses,5 iii) formulation in suitable carriers, including nanoparticles can be used to ameliorate 
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peptide pharmacokinetics,6 iv) while optimizing delivery (systemic vs localized) methods and 
dosing may also help improve therapeutic responses.7 These proposed in vivo optimization studies 
are anticipated to facilitate the translation of this novel biotechnology from pre-clinical to clinical 
utility, which is a long-term objective of this research project.         
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